var title_f6_4_6208="TS forehead plaque";
var content_f6_4_6208=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typical facial features included a forehead plaque in a child with tuberous sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6208=[""].join("\n");
var outline_f6_4_6208=null;
var title_f6_4_6209="Adult mosquito bodies";
var content_f6_4_6209=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anopheline and Culicine mosquitoes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anopheline mosquitoes are oriented with head, thorax and abdomen in a straight line at an acute angle to the surface. Culicine mosquitoes rest with the head and body angled, with the abdomen directed back to the surface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cheryl Whitehorn, MSc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6209=[""].join("\n");
var outline_f6_4_6209=null;
var title_f6_4_6210="Cervical vertebrae anatomy";
var content_f6_4_6210=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Anatomy of the neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 543px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIfAh4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigANNzTjTaADNISfWijFIYFjTdzetLilxSGN3H1oy3rS4pcUAJk+tLk+tGKWgQmTS5NFFMAyfWjJ9aTNLQAc+tGTRmigAyaWkzRmgAyaMmgmkzQAuT60ZPrSZozQAZPrRk+tGaKAEyfWjcfWloxSGJuPrRuPrS4pMUALuNAY0mKKAHZpaZS5p3FYdRSZpQaYBS0ZooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAGaQmijFABRRS0AJRilpM0DCimlqaXApASU3NQtMBUbTj1qXJIpRZZLCkLiqZnpvnVDmPkLhcUeYKomWkMtL2hXIXvM96PNFUPNo82l7QOQveb70ebVDzfejzfej2g+Qv+bR5tUPN96PNo9oHIXvNpDLVHzaTzaPaByF7zaPNqh5tJ5tLnHyGiJR604Sj1rN82gTU/aC5DVDg04EVmLcVItx71aqIlwZoZFLVNbgetSrMDVKSZLiyekNMEgNOBBpiDFFLS0xDaM0uKMUAJmnqc0zFC/eoAkooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKCaQmmM4FIdh9IWxVd5wO9VZbsDvUuSRSi2XmkA71C9wB3rMlvPeqz3XvWbqmsaRqvde9Qvc+9ZTXGe9MM+e9YuqaKkaTXGaYZqoCXNKHqHMtQLvm0ebVPfS76nnDkLfm0nmc1V30u6lzD5Sz5lL5lVg1KG96OYXKWN9JvqHNGaOYdibfRvqHNGaOYLEpemmSoiaQ0cwcpKZKQyVDmm5o5h8pP5lJ5vvVdjTS1HMHKW/O96UTVSLYppkNHOHIaSz+9Spc+9ZAkxThN71SqCdM3I7n3qylwDXPLPjvU0d1jvWsapnKkdEsoPepQ4NYMd371ajuh61sqiZi6bNcGlqjFcA96spID3rRSuZuNiTFGOaAaWmIWiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkY4Un0FLSOMqR6jFAFKW5Ve9UJ74DvWJcaickZ5qhNek96451zthQNua+96qSXme9Yz3RPeo/PJ71zyrHRGikarXWT1phnJrPWQk1IrVnztl8iRcEmacr1WU1IpouJotK1PDVXU1IpouKxMGp2ahBpwNO5LRKDTs1EDTgaAJAaUGmA0UCsSg0oNRA0uaYrEmaCaZmjdQFhxppNJupCeKAFJppNGaQ0DGnrTDTzTT0pDI2phNSEVGwpFIbmgtSGkbpRcdgL4pvm4PWmtzULEg0rjsWhckVNHeY71lO2KYJSKpTaFyJnSQ33vV+C+HHNcetwQetWYrwjvWsa1jOVG528N0GxzVxJA2K4qDUMY5rY0/UBJNGmfvMBXVCqmcs6LR0VFFFdBzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeUalKYtRuoyfuSsv5E1WMhPerXitPJ8SXyjoXDfmAf61QU14tTSTR7dPWKZIGJqRTUK1KlQaFhKnXtVePrVhKaIZKtSLTF7U9etUQyQU8GmAU4UxEgNOFRinjpTJZIMGnCmCnCgljhS0gNLTAKM0UUAGaM0UlAC0tNzRSAWigUtMBuKaRUnFIaAIWFMapWqNqRSImph6U9qjNIojY8VExqVqgekUiJzUJNSvUD9akpDSaA5FIaYTSKsTeeV71q+F5jNrlpETwWJ/IE/0rn5DW54BjMviEN2iiZ/5D+tbUW3NIxrpKDZ6XRRRXrnjhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAea/EGLyvECOBxLCrE+4JH9BWEh4rsPiZbZisboDhWaNj9RkfyNcdGa8nExtUZ7GGlemiUVKtRCpF6VgblhOtWFqslWU5pohkydKkHrTEqVRVEMcKWgdKUUxCinCmU4UxMkFOU0wU8UEjhS0lKKBC0UCg0wA0lFBpAJRRRQAq06mCnA0wFppNLmmmgBrGomqRqhY0ikNeoz0pxpppFEbVA1TPUL1JSIWqu5+Y1O9V39aTLQxjyKYxpx60xjSKIpDXX/AAzh3Pf3BHTbGD+ZP9K46Q16R4Atfs/h6NyMNO7Sn6dB+grpwkbzv2OXFytTt3Okooor1DygooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopHYIjOxwqjJPoKAM3W9astGgEl5IdzfcjXl2+grnk+Iem7wJbW8jT+9tU4/WuSupJdZ1GW7uCS0h+UdlXsBVfUrIRQHI5615s8XLm93Y9KGDio+9ueheI5rXXPCVzcWEqzIoEgZe205OR1BxmvPIjwKxdL1e70q6mNow8uRSkkbDKup4wRW1GQVVh0IrKtU9paXU1oU/Z3j0JhUi9KjWpFrE6CdDVmPtVVKsx00SywtTLUC1KtUiGSilFNFOFMkWlFIKUUxMeKcKaKWgQ+lFJSigQ4Ud6SjNAhaSjNJmgBQKDRmkoAUUUA0lMB1MNL2pp6UDGtUTdakNMNJjRGe9MNSNUbUiiJ6gc1NJVdzUspEMhqFzxUjmomqTRIjbtTGp56UxulIohZS5CoMsTgD1NemXGvaToVvFaS3AeSFAnlxDceBjnsPxryy+meCEvESJARtI7GqmlyedLtk5JPNdFKq6abRz1qSqNJnrOn+NdIvJhEXlgJOAZlAB/EE4/GulHNeN3WnBYtyjBxmu2+HWqPd6bLZzsWktSApPUoeg/DH8q6sPiXUfLI46+GUI80TrqKKK7DjCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKzvEblNB1Bl4Igf+VaNZviSMy6DqCLnJgfGPYZqZfCyofEjzfRk3FPSm+I32gqPSn6M3yJUHiD5sn2rxD2+pyNum/ecetb1k261j9hWTYAGWRTWjp5/0fb/dYimxI0I+amUVBFzVhKRZIvWp0qJRUqUIllhDUq1AtTLVEMlBpwpi08VRI6lFNFOpiHCnCmiloEPFKKatOoELRQKKAA0hpaQ0AGaKTpSZoAdmjNIKKAFJprGjNMY0ADGmNQx5ppNIpAelRsacTTGNIZDIarSGp3qtIallpELnmomNPc1Cx5pGiEJqNjTjUbGgZUuvnkjT2LVV00bdTwOmauIN14/oq4pmmReZqG4etUtjN7nWXeDbqPaj4dsU8S3Kg/K0DZH4rTL47Y8egqb4cxF9fu5f4Y4SPxJH+BrTD/xEZ1v4TPSKKKK9c8cKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApHUOjIwyrDBFLRQB49YboJpIX4eNih+oOKXWCGiya0fFVr9h8UTkDEdwBMv49f1BrM1D5oDXiVI8s3E9uEuaKkc1ZnZeOPWr1g2DKvvms84S9B9avQ/Je47MDQxo1ITVpKqRHmraVJZMtSLUS1KKCSZTUqGoFqRTTJZOKeKjWniqJY8UtNFOpiHClpopRTJHinA0wUoNAD80tNBpaBC0hpaKYDTSGlpKAEoooNAxM01qXNMY0gGk0wmlamGkULmmPTjUbmpKIpDVSVqnkPWqshpMpELmozTnNR1JogNRE81I1Vrh9kLt7YFNAyG3YlZZP7xq/oEeZ95rOJ8uyUfxNW3oyeXGGPpTexmWdSk+VjXRfDK2K2F7dsCDNKEHuFH+LH8q5DVJcqQK9R8N2ZsNDs7cgh1jBYHsx5P6k104ON537HNjJctPl7mlRRRXpnmBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHIfEWy8yxt75B81u+1v91uP54/OuKlO+DHtXrmoWkd9Yz2s33JVKn2968jVHhkmt5hiWJijD3FebjIWlzHpYOd4uPY5m8yk4Poauu2JIJPek1aDqRUPmB7IeqmubodRtRHmradqz7d9yK3qM1fiOQKktFhakWo1qQdaRI8VIpqIVIKoTJ1NSCoUNSA0ySQGnCoxThTJHilFNFKKaAeOlLSClpkiinCmilFADxSGkpaBCUhozSUxhSHpQaQnFIBDTDTyaYaQxpphp9MY1JQ0moZDT2NRMc0ikQvVZzViQ1XekWiB6jqV6jNIpEbniqV82VRP7xq3J1rNuXzc+yimiZD3/eTog6Ct+I+XCAOOKxdMjMku81r3LiOImiQoon0GybVPEFtBjMUbebL/ALo7fjwPxr1muR+HWnmDTZb6QfvLpvlz2QdPzOf0rrq9XDU+SHqeXiqnPO3YKKKK6DmCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvPfH9h9k1KLUI1xFP8kmP746H8R/KvQqyfFNh/aOhXUCjMgXen+8Of8A6341lWhzwaNaE+SaZ5NfRh1z2xWHH8kkkR6HpXSQL59sB3HFYeowGJ/Mxyp5ryF2PXZc0x91uAeqnFasJ6VhaTIDLIo74YVtxGhlIuJUgFRpUwqRAKcKMUopiJEPNSioRUgNMTJBTqYKcKBDhTgajzTgapMRKDTqjBp4PFMloWlpuaAaLiH0UlFO4WA0UUhpXASkPWl/Gii4DTTTT2phpFDTUbU80xulSUiJjUTVKwqFqRSInqvJVh+lVpKRRE9RNUjVG1BRBKwVST2rJX5izHqTV3UZNsW0dWqOyh8yVB2HWqREt7GppsXlQjPWpoLZtU1W2sYzjzXwSOy9SfyBp7YjiOe1dJ8ONMLNNqsw+9mKHPp/Ef6fnV0Ie0nYitP2cGzuIIkghSKJQsaKFVR2Ap9FFeyeKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5Nq1t/ZWv3Vrj93u3p/utyPy6fhWdq1uGQnHBFdz8RdM86zi1GJf3ludr47oT/Q/zNcgWE1tg8kCvIrw9nM9ihP2kEzkLRmtr5VboDj8DXUwnIFc7rcWxw69Qc1t6ZL5tvG3qOayZotNDVi6VOtQQ1YSpGx2KAOaWigQDrUgNR0oNMRKDTs1GDTqYmOzSg1GM04dadmK6JQacDUQ96WnqLQlzRuqPNJmjURNuNAaowCelLtb0NAyTPvSZpoVj2NNDAjINAEmaM0zNRz3ENtC0tzLHDEv3nkYKo5xyTSAnNNNZ/8AbukY/wCQpYf+BCf40065pH/QUsP/AAIT/GizC6L5pjVROuaT/wBBSw/8CE/xpja5pP8A0FLH/wACE/xpWZV0XGqJhxVQ63pP/QUsf/AhP8ajfW9J/wCgnY/+BCf40rMd0WZKqydahl1vSv8AoJ2X/gQn+NVZNa0vn/iZWX/f9f8AGizKTRaY1Cxqo+s6Z/0EbL/v+v8AjVe41vTEjY/2hZnA7TL/AI0WZXMiO7cy3YReea3tJtdoyRz1NcxpGpaa0pmk1CzBJ4zMv+NdPBrekxQn/iZ2OT/03T/GqknsQmtyS5ikurmK0txmWZwoH1r1mwtY7GzhtoBiOJQo9/evOvA+paNJqE9/capp6+V8kW64Qcnqevpx+Ndv/wAJHof/AEGdN/8AApP8a9DCU+WPM+p5+Mqc0uVdDVorK/4SPQ/+gzpv/gUn+NWbHVNPv2ZbG+tbllGWEMyuQPfBrrOMuUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADZY0liaORQyOCrKehBrynxBpNxoFy4Ku9ix/dy4yMeh9D/OvWKR0V1KuoZTwQRkGsa1FVVZm1Gs6T0PnfVrhJmCJyau6FIVzEa9H+IOk2cPh4yWtpBCyzKzNHGFPcdvrXmsA8m5Rh07151Wn7N8p6NKp7RcyOkhPSrkfNUIjg1et2+dc1lFXaRrN2VyYIacIyatrGDMg/vLmlhQGPd+VdqwhwvFPoVPKOcU7yeg7mr2weYw/ugCnhACD6DP51rHDRRk8RJlFowtL5RAFVfEGrW+kW5mnyzLwkY6u57fhXN6X43FzdrDe2ogWQ4jdWyM+hpuFOLszWnSr1YOpFaI60Rnd04pwjzIBVhQDvx0I3CiFcyOfQCtPZROX2siEx/vMUeUdw9xUwwXY++KlCjf7BRT9lHsHtJFNo6Ywxg9qsvxGT3NQlC1u5Hak6MX0BVZIvX8S2EcDsvyyOE/Qn+lTRxxPjGADj9aofES+FtoGlsBmWWZCADj+Amsqy1W9a3AexVlII4cjIP4Vy1KmHovlm9TojGtVXNHY66O3SJgWxXj/iTxTdeHtFsDYwxXOoahfRadaLOxEYkkJALkc7QAeld9Lr8wgdpbKXzhGdoRgwLgfKe2PQ155qFna6rop0vW9Nnlt8q2RuVkZTkMrLyCPUVxYutRk4cjuup04elVSlzblvxNrvivwt4H1PVdSstHv761bcptXkiiEWPvMrZJIbjaDznORXXWgTVtDtZLuGJ1uII5XjZdy5IDYwfeuH/wCEc0q+0CfRbiTXJLW6lEtxJLfSPJLhdu1mYn5cY+XpwK7XQre10nSLaxhuJ5IoF2q1zKZHxnIBY9cZwPYCuCdW0fdetzpjB312Mz7PolvKYrzSbOMg8P8AZlKn8hxV6HStDnXMNhpkg9UhQ/yFWbmewl4lZG/Gs2bTdLuDlSmaqGLkl7w3ST2Lh0LSP+gXYf8AgOn+FMbQ9J/6Bdh/4Dp/hVAaFg5tJ2Q/7DFT+lSjRL2T5ZdQuNnp5hrT63HqT7EmOh6T/wBAux/8B0/wqJtD0r/oGWP/AIDp/hUWlWws9VubeOR2RY1YgnPJJ5/StaStoVOePMS4pOxiy6LpWf8AkG2P/fhP8KqyaNpf/QNsv+/C/wCFa8p61WkPFVdlJIy20fTP+gdZf9+F/wAKyr3TNOlk2R6fZgDriFf8K3LyXy4zjqeKqRRbYi5HLVSbBpbFTTdP0kIFews8jrmBf8K1bTQbPVbtLSw0qyeRup8hcKPUnHAr0+Lwho7WVtFdWUckkSBS4JUse5JUjPNa+nadaabD5VjbpCh67ep+p6mu2OEle8nocMsXFK0VqZWl+ENDsNPgtv7K0+QouC7WyZY9SelW/wDhHND/AOgNpv8A4Cp/hWrRXalZWOFu7uzK/wCEc0P/AKA2m/8AgKn+FYNjYWdh8UGWxtLe2VtGywhjCAnz++BXZ1yv/NU/+4N/7XpiOqooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDH8YW5ufDWoRr1Ee/8A75Ib+lePkBovevdZo1mhkjf7rqVP0NeGBSjOjdVJU1w4xapnfg37rRqWreZAjj05q7GeKytJk/dsh7GtaNMjiuDZnduhIfE2ngRyNOpIjOQvPNWLPXtOcRRC5UEAZ3cV5ZMPJv72LptldP8Ax41YtX+aR/TJ/pXorESKeVUraNnrFhqFreOywzIzM5J5qzcXUMFs80jAIMuc+g6V5jpuYkkkBI2jaPqeKztY1m7mdrTzmMBHzKfT0q1iNNUYPKuaVoS0DVNQk1jVmnlJ8onEQPYev41Wv7fy1G3jPI9jS2cecr0J5U1NeSeZbejD9CK5W76s9mMVC0Y7I9S0S5F1p9pLn79uCfrgVfhYIkzH1A/If/Xry/R/Etxb6bawW6qGRCpZue9WX1i+n+zq055O4j9f5Cuv28bHhSyyo5Poj0QHbEv94jP4mrDnbGx/CvObLX72K4aaSQyxp/Ax4J7Vtaf4o+3XUVtLEI95+8DxVxrRkY1cvq01fdHRXDYUDpxVi0QPaS/Ssm4naUySD7oPFQ2urmCN43zyMZFanCP+JHOm+Gmb7gJyffYuP60/+39PgskQum4D1rQ8caf9t8I6UCBvjkiPJx95SvP51y9v4CvLiXg26jG7li3+HpXj4zC1alVygtGelh69ONNKb2LH/CQQ3BYRIWHsKzNS12O2yJCiv2QcsfwpninQ7rSY7KKC6JeYSb0Q7B8u3oQM9+9YlpG+nvvk0zzW6lt2f515dSg6UnGW5305qceaOxI+o6tfHFvE0KH+IjmqdzZXAI+0zzO57Fj/ACrrdK8Q2Nw4ilh8mTurDBFMvBBJrVqQQUMyf+hCpi3e1rFPa5SsPBM8saSXLx26uMgFdzfj0watSeCpoRutLuJm7B49v6gmu3jLxggDzIz/AAmpY0SYHyH5/uN1pU63s5ezxMbPv0/r+rGDm94s4GP+2NHPz2JljHVovmH6c/nVhfF8JXDRMr9MH1rr5FKsQwIPvVOeztp33TW8MjeroCf1rpeHhNc0WNVX1OY0CZr3V7m7AbyzHtLEcZyMD+dbsvSrLosahUUKo6ADAqtIeK3jHkVhXu7lGaq0h4qxNyaoX8nlwse54FMsoyZuboKPuitrQbQXuv2NsBlA4dh7Lyf5VlWKbEMh6muy+Gln5t7eX7DhAIk+p5P6AfnW9GPNNIxrT5IOR6FRRRXrnjBRRRQAVyv/ADVP/uDf+166quV/5qn/ANwb/wBr0AdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXjvi62Fn4lv41GFZ/MH/AAIAn9Sa9irzz4oWWy4s75Rw6mFz7jkfzP5Vz4mN4HThJWnbucXp8uy8ZD3ro7R8jmuRR9uoQH1OK6W1fBry5Hpo881bjXb/AB3uXP6mpLMf6OSerED+v9Kr6s2dZvj/ANNpP/QjVm1+7Gg9Sf6VvHY9d/CjULCOxHuSx/kP61zBbzLiWX/ax+Arc1aby7dgP4Rj/P51i2Cbk5696phTVk2akK/6Nv7pz+HequpSBct/eHP1rQssKjRt1X9RWTqGBmM+oA+lAR1kSWalYwB1wFH1rWBG6Vx0QbF/z9P51nWwwy56KNxrRWMlY4uhJy31PX8qEKe437tuvq53H6dqrxnmSXP3BtH1NT3jgbj0HQfSq02Y7eOIjDH5m+p/+tQJHoGlTs2h27Ocsw/rT2t0dRxySKr6Mh/sq3LZwqcVeg+5ubswNejD4UfJ17e0lbuzsfGihPDjdBskiI/BxTdJlIt1KuNwcrk9M8DH5gf99U7x3IIvDc7lC+JIvlB6/OtefNrmoxq0SvBbI4AO1d7dMdTx+lYV8VToO03qVSw86usdjpfH0McmmxXYyHimXGeoJOCp9Ov44HpVS2himt1LopOPSsMme/nV728muMY4duOOnHSrus63p3hrSH1DVrjyLVCEGFLM7E4Cqo5JPoK+fxlZYionBHq0KbowtJlXWvDkVz88XysOQRwRWNYWk0esWltdTBojIPm2/Nxzj8cYq/L4509tEkvxYa2Cs/2drY6bMJwxUtnZtzt2gnd0/Hisvw5ren6vqGmaxaT+Zp05LJIQR1ypyD0IPX6VlFTguaS0RrzKSsmemoKSSNWOejeo608AqcN0PRuxocYr0V7LE0+6ONXiyvKScbmJIGMmou9SyCojxTUVFKMdi1qQTVSlNXJu9UZjzSZcSs+M81jao/mXCRjpWnM/NYavvvpGPODihFsuyny4Me1eoeBbM2fhq13DDzZmb/gXT9MV5zotkdX1m1tMfIzbpPZRya9lRQihVACgYAHQCu/Bw3kcONnooIWiiiu488KKKKACuV/5qn/3Bv8A2vXVVyv/ADVP/uDf+16AOqooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArL8TaaNV0a4tgB5hG6Mnsw5H+H41qUUmrqzHFuLuj54uRskiY5GHGa6SE81Y+KGhnT5XvrdMW07bjjoj55H49fzqpCeFPqK8etFwdmezSmprmR55qB3arfe87j/wAfNaGnrmXnoOKz7jnUrr3uH/ma0bIYglbvg4/lWqPal8JW1qTdEij+M5/PmorMbCD2NR6qxNxGo/hGas26Fovl5I5FA9ol+YbFRx/un6dqyLjEl4me2TWlM/7naTlSKyISXnYHtxn+dAoI1tPj3vk9PvH6dq1I1Hzyenyj6nr+lVLQeXbggfM3P+Aq7MRHCFHRRz7mqRjN3ZRdBLcqp+6vzN9BVO7cyTE9yat7tkLuesh/QVVsojc3iqBnJAH1NItaas9JswP7Lth/0zBP0qa0TfC+elOmjEFio6AgKv8Auirumw5tGOO2a9JaI+Qm7ybNfx24bw/CpOPNniAH47v6V43FJJ9qkSY/OjkMPfNen/EG4/0TQoR/y0kMv/fKY/8AZ64XxdpElrMdQgUlGAMqj+YrwMxlevbyPWwStS9SxFOoClTVDxpotz4o0ixTT7qG31HTr6HULUzgmJpIycK+OdpyelUdKF7qE3lWMLye4GcVrmz1ezvPs6QrJIihnG/7ue3T/Oa5FTnBe1S0R0ylCT5G9SHXLT4gan4WuLW2uPD9lqk8uwyQyTbYoNvO1ihPmE99uADxzzVXTdDk0PwvY2Fza2VtJaqY/Ks5Hkj25PO5gCSepyOpNd7p/neQhmG1iOQe1Y/iN1KtnoBWSqtrltoEYWlcx/Dd7PGZLRdUnhEZ+QNh1KnkcNmujivrxL+1txepctK4GwoB8vc5HoMmsrwt4etNUsJp7kSJJv2JIjYIAH5d63dM8MwabKZ1uJZbjGFd8YUewrf2FWMfaUtyJThdpmtKrKcOpU1C1Th5fLKSsGHbFV5OBXRQlUlC9VWZjpfQrTHg1mznrV+U8Gs+fvVs1RRmOATWDZNu8x/Vq2rw4ifHXBp3gPw9LrLKZQyWaNmV/X/ZHv8AyrWnBz0RNSSjqztPhvpJt7OTUZ1xJcfLHnqEHf8AE/yrtKZFGkUSRxqFRAFUDsB0FPr1oQUIqKPHqTc5OTCiiirICiiigArlf+ap/wDcG/8Aa9dVXK/81T/7g3/tegDqqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKup2FvqVjLaXib4ZRhh/UV5NJF9muJYASfKcx5PfBxXsdeRasf+J5qQ/wCnmT/0I1w41aJndgW7tHmch/4mNx/11kP/AI8a07Xiz+uP8ayJji+ufaR//QjWxD/x6j25/SsYn009kY07b75/bArSssIwX8jWSObiRv8AarSQ42t6cH6UFSWlhbpghZO3UfSoNNi3sXb7pOT9PSk1Fi2MHnOKuWKEIqqPmPQe9BO0TUtU3uWP3V/nRd/MQgOM9T7VPEojjCg5A7+pqvdHYCT94j8hVHOndmffSfLjoOgFb3gXTjc3yuw+VOSfeuZkJkmHoK9T8JWX9n6MjOMSyjcfYVpRjzSMMwq+yo2W7H63Ll9qj5V6CtfSMNat/u1i3MZk3Me9RWmom1yjZx0zXcfNF/4g280uiaHcW5USRsIxn/aUf/E1V02+bUNLubXUYxFdwLhgw/Wuj8SQCXwMGc7WijimB9CCD+eMiuE1y7mlMNzFC8cxiaJ2I4cZyB7nk/hivIzGlTS57+9+Z6ODnN+5bTudH4MlsrLQZH2rCodt0gXOc9AfUc4/Cue1W11S51Ga/s5GhM2Pk6jAGBn3wB3qTTSIrS2hnZWMIJCKOAxOST6nnGfaty3n8wDivPxGLc4Rpx2X4nXSoKE5Te7OVB8SrxhG9yCP61BPpurXQLX8wRO4UYro4PEuhXDXIt9a0yU2qlpwl3G3kqDgl8H5R9azrrXLDVbUSaTfWt7AW2ebbSrIme4ypIzXL7y6G6knsavga3NvY3Cj/UmX5B68DJ/z6V0UlY3hGeKfR4jayCQqWEiE8htxNbBYMODz3B616OGxEJx5E9V0OKonzNkD1VmNWnqrMK2Y4lKboaoXFaEw4NZ9xWbNomdKu9wn947fzr2a3hit4Vit40iiUYVUAAH4V47EM31uD/z1X+Yr2avQwS0bOHHfZCiiiu44AooooAKKKKACuV/5qn/3Bv8A2vXVVyv/ADVP/uDf+16AOqooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8j1wbPEepL/02Y/nzXrleVeLE2eLb8Dodh/NBXJjF7h2YJ++15Hksv8Ax93PvI3/AKEa11OLU/7p/mKyZf8Aj8n/AOurfzrTJxaP9B/M1zI+pl0Mq2wzv/vGrsbYUg9uDVG0ODn1qaaTZ83Y9aCpLURCZpwD0Q/ma3bBNqhz1PC/T1rM06DON/QfM/8AhWxGSSPU9BTRlUfRFkYxk/dXr7n0rMv5jz3Jq7O+yPHYfrWQ7ZYu3QdPrTZEF1LOkxK2oQCQZQMGevWwCyJGoxkfkK8x8MW/n6jAjD7zh39lHNeqD5IWYj5m/QeldOHWjPHzaV5xRn3JC5rPngV13DrVjUiUUAn5iamitzJascdBmuk8g2viJL9k8J+SvSSWKH8Ac/8AsteY+J9Yn+1RWULbYwoLY4Jr0H4pPnRNMXP3rpW/KNv8a838YafJHPBfRqTEUAYgdK8HMWnXs+iPYwKtS+Zc0tjtBNaPiG0utW8J6tYadKIbu5tJYYnzjDMpA57devauctNQjSMA5J9BW3pmpRtOsRJVz0UnmvOaafMuh1tJqxzXhBPsHhyG0n+HVzFc2GnrBOxitz9oYMm5IzuzJuIMmTgZXuSKzPh5o2oaYutXF/p89pDd3wnga6SOOeQbQCXSM7F5HAUDvXssR3RD+tZeuRB7Yk8EVX1hu6tv6mcaSTTvscvockcBZPMkinjZlLRuVOMn07V0emaw8msQW0s7zxPndvAyoAPIIAPXHWq2iaPZaxbTfaFeOdHGJYjtbBA4PryDXSabollpsLrAhdn+9JIcsfxq3hHUjzK2pM6sU7NFTWfEWj6Tcm3u9QCyhQxQxOxwenIGKyZfG3h49NQ/8gyf/E11AiWInaWwexNRy11YaM4QtV39b/oYPfRnL23ijR7+6jtrS88yaThV8pxnjPUjFee3PjzUV8bS6RfCw0qIXwtoIr23m33cWQPMSYHYCRkqpHoM16/KOK4u88E6VLqa3lw9/OEuTeJbTXcjwJNkneqE4HJJA6DPSt4uCvdFNSdrM5eP4i2dytrPFZ6haRXMdxLa3M0Ubq7Qbi42CTORtJAJUHGMivSp/jHY6bpFpLNpOtapMui2us3c9rbRRokEq/fKtKSp4JKgtjPU4JrzXw78O7HS9Ogi1aaa8uESeLIlby4kmdi3lqeFJVsE/WvbB8NPDwsrm1Edz5Nxo8WhuPOOfs0YIUf73PWu/DcuqicWK5vdcjM1v4u6Lo/ifTtIuLW5dL57eOO5jmgODMAUJi8zzQvzDLbMdcZxWh8OvF11rfgO613WUj329xeKy26YykMrqMAnrtX161Bc/Cfw1PqQvT/aMbedbXDwx3jrFJLAAI3ZM4JAUD/6/NdDonhXTNF8O3GiWKSixnadnDPlsyszPz9WNdRyHEWvxu0FraS61DS9a02zOl/2vbzXUMeLmEMq4QI7fNuZQAcdeo4ymn/HDw/eWM0yWOoyXEV/a6e1vatBdMXuAxiKtHKyMDsYEBsgjGK6B/hh4YltLK1ubOW4trTS20dIpJSQbdipIOMHdlQQ3BFOi+HOkiK1jur3Wr4Wt7bX8JvdQkn8uSAkxgbicDLHPc8ZJwKAKNx8VtJtL+SwvdK1q21MS2UUdnLFEJZWus7Ng8zB2lWDZIxtPWq+h/GPw5rPjaLw3ZrOZZp5raG48yEq8kQJYGMOZEBwdrMgDY4rpdV8E6JqnjLSvFF7bM+r6ZG0dvJvO3B3Y3L0JG9iPQmodK8B6TpGtPqGmT6pbI873TWMd9KLUyvnc3lZ28kk46Z5xQB1dcr/AM1T/wC4N/7Xrqq5X/mqf/cG/wDa9AHVUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeaeN4wviaRh1eJCfyx/SvS6838cHPiVh/0xT+tcuL/AIZ14P8AiHjMv/H5P/11b+Zq9I2LN/w/rVGX/j8m/wCujfzNWpm/0ST/AD2rlR9W+hRthmL3FPX9/MijtyahD7YVI9MVf0yHau9vvHk+1BUtNTShQRxgDp+pNW0Hlrlj85/QUkEeAJXGP7q/1qO6cjpy56Cmcrd3YZcuXOxT9T6VQkYPIAB8i1LKxHyLy7dTTETMgiU+5NBolY7T4eWqyST3T4JUhR9a7dzkkn7q/qa57wRbGHS8oMNK3y57Ad63b1xFDtXkDge5rvpK0EfMY6fPXkzA1KcNdKOwOK6XTI99o2B/DXL6lDhQR97rmr2ja4LeIxT8H1rQ5DQ+IkUkvhPTpo13SRSxtj1yjD+ZFc/pmordxrY6pB5LMMKXGP512PibafAwkc7QqwyA4z/GtcxczLqOkpbzWMjFPuSsyoV9CG5P6ev4eVj6NFvnlK0jvwlSpblSuiHwnpmnrqN7/oyStCy4DcjnOcf985/E+mKztbtJ7vVprvS7eKSFCEBY/eK8bgR/nvS6bC1t58U1zlZipdIz94jPU9e54rfs5lCbQFSNR9ABXmVMVejGkltud0aNqrqNnMnXdXgwk2nuf93FQ3Go6lfLtSwlX3YgCui0fxHoet3E0GkatYX00PMiW86yFRnGcA9Penpq+n3ti8+m3lreQhzGZLeVZFDDqpKk8j0rld1vE2Uk9hvgbelrcxzKonWQMxU8YI4H6GulbpWN4a2fYGuVwRNIxLA5xglcfp+tbBORxXqYarGcLJ6rc46i95sifpVdzkVO/Q1Rmfaa0YRQjjNUrheKs+ZkVDNyKhmiMS/BCNXsdvIJoI5V+66hh+IzXkV6mVIr0nwjc/avDli5PzInln6r8v8ASu3BPVo5carxTNiiiivQPOCiiigAooooAK5X/mqf/cG/9r11VcFrmrf2T8Ton+wahe79HK7bOHzCv77qeRgUAd7RXK/8Jl/1LniT/wAAf/sq3NG1H+1LM3H2O8s8MV8u7i8t+Mc4yeOaAOV8P/EnTvEGsC10jStcudPad7ddXW0H2JnTO7D7t2Mgjdt254zWta+OPCl3Fey23iTRpIrIqty63se2EswVdxzgZYgD1PHWuM8KfDvxD4d0qTwtba/YnwZ/pCxx/ZG+2rHLvPl+Zv28M5O7bnj8uYT4F6gfDt5pc+o6bLIbGDT4bxjdvI0UdzDMAySTPGi4iI2ooGW4wMggHsMfi3w5JBPNH4g0hoYIzNLIt7GVjj3FN7Hdwu4FcnjII61Wj8ZaQlvq11qN5ZWFjp1x9ne5mvYCjEqGB+VztJ3cK2G9uRXKfEL4VQeKNd0S6sJ4NOsYEFrqVqkWBeWonScRDHA+dCf+BH8a+o/C6+nvdR1C11O0S9PiJNftFmgaSHKxCMRyLkH1O4HI4xQB2DfEDwejWAbxPowN8m+2zeR/vV3Fcrz03Ky/VSOoNWfDXia21+/160toZo30i9NjKZMYdgitlcHphh1ryzx38JvFXi+2uY7zxBpaLd2wjkgihnhghkEzybkRZAHJDYLSBjnJGM16R4M8MTeH9V8U3c1xHMusakb6NUUgxqY0XafU/LQB1NFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeY+MZRJ4quVHPloin8s/1r06vI9VlFx4i1KVfu+cVH4cf0rkxj9yx2YJe+2eVz8Xsw/wCmjfzqaVsWsv0/pUU4zfT/APXR/wCdMun/AHTKO9cqPrEr2IoV8yRR/COTXQWEQIDv9wdB/eNZenwcDd35NbsXQADnsPSmjOrLoTFiTxyx6CqtwQnfc5/WrEjiJMDlm/M//WqjIxVsn5pD2HamzKKI2Plj1kap7CEyTRwoNzOeT61XbEeWY5c/pV3QoWm1S3TnezjgdhQtWVN2i2er6VCLSwReNwUD6CoZiXzI33f4R/WrW0MgT+Bfve/tVS9fg16SPj5O7uZpfzJsHkCm3VihKlRgmlRdpB7k1pSRH7OHxyKYi58T3+y+FLaFDhWuIo/wAJ/9lFcRr1/JFDaWyMUWQZJHeus+LjmTQtLx0e7Vv/HG/wAa53XtMa80SKaEDzYfmHv618/mTvXVz2MFpSMmCZYgMcue9L4isLrXPCGsaZZzCK6vLV4o2JwMkdCfQ9D9az7e6iWHMuQ4OCO+a0rfUntXiMlvIFcZUY5I9cVxJST5orY65Wa5X1MbTdN13U/CTaJaeG4/DF7HYpaNfyPEwIyodI/LJbDAMd3GDjvyKnw00HV/DXhvVLDVbWC0jOpyy28cWfuHAyOT8vAwOvHNeqWl5HNAr5IyOh4qvqpilt2+YZApPESacLaMzjSSkpdjC8IS3Fvp6yWk6gknzIZOVY/0PvXY6RdQ6laCZf8AR5clSm7cuQcVyOjeHEvoJJre+mgPmMsiAZGevHpwRXW2elW9pZxwQ7h5Y+/nknqSfxpTwdSX7yna/wB35EznC9mWpI3T74GD0IPBrNu15rRVGVArMW9zVa5TKmu+iqipr2u5kmr6GWGpWORTJRtY0gORVmhVuVyDXRfDq82yXdgx4/1yD9G/pWDMMiq9heNpmqW96gJEbfOB3U8EflWtCfJNMmrD2kHE9fopkUiSxJJEwZHAZSO4NPr2DxQooooAKKKKACuV/wCap/8AcG/9r11Vcr/zVP8A7g3/ALXoA6quJ+Kni+78D6bpmtCGGXRlvUg1QsjNJFC+VEiEEAYfaDkHOa7aorm3huoHhuYo5oX4aORQyt9QaAPAtd+K/jWytfDsDWWjWep6ho51dmn2RwSMZCEt8zXEe3CbS5DO2W4UDNaOseO/GWsWPj0aM2i2FpomlRXXmBZJrjMth5/7t1fYSHPDYIxjg9/abuxtLyJI7y1guI0OVSWMMAfYGnR2tvHJK8cESPLjzGVAC+BgZPfA4oA8A1D4qeKNP0Pwla2N1ol5e3+ktetqD+WsM0q7QICZbmNQwz87BmbuExnGenxI13TvFPiXU4NQ01pJ5dEZdDlkNw0/n20W9LVlk2gDezblVg2Afr9ENpOnNZpaNp9obRDuWEwqUU+oXGO5pRpdgLxbsWNqLpek3krvHGPvYz04+lAHkk/xI8QxaD4z1q9k0i00vSNVudJtjHaSSzGRLhI0dgZVQjazZyyjdg5ABB52H4z+JP8AhGmMsOmNejXTpLahEsRhRPKEgYg3Ai3k5X/XBeOpPX6B+w2nkzQ/ZYPJnYtKnljbIT1LDuT3zTE0ywS2kt0srVbeX/WRCJQr9ByMYPQflQBgfDHXtQ8R+DbPUNajso9RZ5I5hZTpNESrsoIZHdeQBkbjg5HauqqO3ghtoEhtoo4YUGFSNQqr9AKkoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCC/uVs7Ke5k+7Ehc/gK8gswzAu5y7ncT711/j3VBJt0u3YHJDzkHpjov9fyrmYExgCvMxlTmlyroepg6bjHmfU8uvDtvrn181/8A0I1XiVppP9kHmpdSDHVLpF6+dJ+HzGrllByFTjHU+lSj6S9kWbSIgBVGW/l9a0UGwFU+Zz1J/wA9KbAgC7Y+F7saSaXb8kQ57n/GqOZu7Ip32ttX5pDUJ2xKWY5Y96V2EYPOWPU9zURUkb5PwBoLSI8l23N+ArqvANk0+otP/DGOvua5VR5jHHAHU16l4Bsmg0nzHXarncB7VrRjeRx5hV9nRaXXQ3pQFQKowBWfcr1z0HWtKYlnwOp/SszUWAG0dK7j5kxWuCt2oP3c11Fq8TWMgcjOK5WaEyNuHWpY7iaFSpyR70AdB45sDqfhnSSHKFJU5Az1Uj+eKx9Kee1S4sL8qW8rfGwPDrXR+Ky9v4GiAwJv3IGex3Kf8a891l79lheaeEMFKAqdpwa8fMvZX1+I9LBe0a/umr4f0TTp7aXU7wYAlOCThRjHP5/zqDX7Ftbvjc2++CCNQkIAxwOvHpnNUbK6hs7aKIM05TkbjlQTySB261qQ6jsje4uJFSGNS7seiqBkmuCriW6apQVl+Z1wo2m6knf9DAFlrMOUhm3L6MtVLrTPFcswa2vrGCLbyJrV5Wz65EijHTjFaGnfEa3vdMutVGg62mjRWs13HfPCgSZIlLHA35GQDt3AA+1aPhDxjbeLdMnvbLTtRtLZURkku1jAlDAn5djt0GM5x94Vi1UhdtbehftIy0uVfCVr4sFvcwxa1oi7XDkyaRKxJIx2uR/droBZeMP+g74f/wDBLN/8l0eFJo2W7EbBphId6fxAADGPUda6ONw3Q/hXdhsVCa5L6roctWnaTZzbWXjD/oO+H/8AwSzf/JdVPHBv7T4Z+IpLm6jbUItLun8+1jaABhE5BVSzFccfxHkZrsTzTGXIrpb6maR836ZNrXhT4eWet3t0YpNVWyWG6W8lusB0LFphP8kI5XJXcMnHpT9N8e61daRox1HU7XTLea4u4LnV/s4dAYiPLXn5VLZPJAzjgZr6BuodynismaIox4odRdUXGD2TPFB4619vFVraG+sVtvNtVSOaLyft0LqpaVAfmySxIA4XGCOtbPwru726g1631XVmv7u1v5Y2hkUh4RvbBOSTtbHA6DHFenEcVVuollieN87XBU4JBwfcciolUTVkrGkabTu2ebeEPHmq6Klzo8mo2mj2cniK6hu9ca1DCFVgVlyrEqC7ALk8CtmL4g+IWQ65eWdra6yngi61AO1uVJdLsKjbSeEdQr7f9qtjQtJtfDSY0ONrY+cZyxkZ2aQ9WZmJLE47mvYfDurR6xpyTrhZR8sqA/db/A9a9DD1lP3TgxFBw94+fPHfizxvD4f8R2U3iEGSHTdM1hLmytDbyQpLOFkjBVidoHzEkk4BB4Jr6H8PXAu9DsLhb+LUhLCri8iQIk+R99QCQAevBNaFFdJyhRRRQAVyv/NU/wDuDf8Ateuqrlf+ap/9wb/2vQB1VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVHcTRW8LyzuscaDLMxwBQBJXNeJfE0enFrW0AlvMc/3Y/r6n2rI17xc9yGt9I3JH0acjDH/AHfT6/yrmYYjkliSx5JNcNfFW92B30MJf3qg5FZmLyEs7HLMTkk069vINNtGuLl9qDoO7H0HvUGqahb6Vama4OWPCRjq59BXA399c6xdiS4IwvCIPuoP8feuGMXLU9ejRc9XsQgfabyecDYJZGf3GTnFa9vAEQb8Knp61HZwBPuLvcd+wq4AqfMx3MPyFdKR1zl0QpyUH8Cfqf8ACqU0oU7Ixk9gKlmleX7nTuxqszpCDjljQxRQoQJ88hy38qryyGU8cIO9PZWYbpjgdlpgXzOfuxj07+wpFo2fCelHVtQEeNtvFy5/p9a9ejRYLdI4lwgGFUd65bwBYC20zzmUgynIX27V1E7iJSzH5/0Wu6jDljc+bzCu6tVxWyIZCI8jOXP3j/Ssi6DSynHCjqaux7rhiRkJ6+tV7tgvyJWxwFFADLjsKnmgBjzjpVeLAlrXWLfZufagC78RmA0qxhBwHuV/IKx/wrxszvdXMjyk8EgD0r1f4guXh0Jif3bOxP8A3yP/AK9eeeINJfTrlriNSbZzlv8AZ9/pXz+YP9+16Hs4LSkinGxQjPStSOJb+xntJwWhnjaJwDjKsMH9DWSlwHwkabie9X4Z7uyljjeE5YbsBe2cevsa4nGTV0dba2IvDHhDxDp+gtoz+IrOfSY7WS2t4pdMV2IYEKJcth1UcYAG7vVrwb4Ik8Mza7qNzdWst3qfl7obK1FtbxCMEDagJ5OSSa6y0u4lhUs4yR0qHU9UhSBl3LuYY61LrVJXXffRGapRTT7GBpWP7SuohIYZARJHIDggkDPP511OlaoZL77FqJjeUoXSeLgnHYj1+lYum+HrfV7f7b9qniLsVUxMMFRx6eoNbmkeG7LTpmlDTTysu3dK2cD2wBVywcqsbq1+hM6kNmbqoQMrIHX9aUimW8KwghM8+pqau7DQqQppVHr95xzavoVpFqnPCGFaLrmoHWtmiosw54SpNU5K35ogazbi36kVk0bxlcypFzT9H1KfRNRFzDlom4lj/vL/AI+lSSRkHpVeWPI6URk4O6LaUlZnrdpcRXdtHPbsHikUMpHpU1eaeFNdbSLgW1yc2EjdT/yzJ7j29a9KVgyhlIKkZBHevYpVVUjdHj1qLpSs9haKKK1MQrlf+ap/9wb/ANr11Vcr/wA1T/7g3/tegDqqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiqOraraaVB5l5KFz91ByzfQVwms+Kb3UyYrMNaW3QkH52+p7fQVlUrRp7m1KhOptsdbrviSz0pWQMJ7roIUPQ/7R7VwGo6he6vN5l7KSmcrEvCL9B/Wq8cIXtk0+eWG1gaa5kWONerMa82riJVNOh6dHDRp7asdHHjgCs3WtdttKRo1xNd9olP3f949qwdY8USXAMOlhoo+hlP3j9PT+f0rEgti53SE88n3/GojTvqz0qeG61BZXudSujNdO0kh/ID0HoK0ba0WMfN+Q/xqW1tzs+RQqep4FWSI4xljvP5AVukbSn0Q0NhcIPl/IVDI6jljuP6flTZZy5O3Le/aqruu75jvb+6tAlEe0jyH5Onr2pmUjPHzyetMeRmwHIQf3R1pDuC/u1C57t1NBdhWyxzMeP7tbfhnSZNWu1JH7hDye30rJsLM3VwsaBpXY9+ler+GtJewsFj4QnlmI/kK1pU+Z67HDj8UqMLRfvM04BHY26xoMuBgYH8hUfkvK26fp/dq3GkaH5QZH9aZcJLIMEqo9M13HzTdytLMkalRismeT5jgZJrSe2ReZJCT7cVXlSEdFz9aAMkSFHBYcZro7SaM2EgyM7awZk8wkAVWzcwZVWO30oA6HxtYyXnhfSZIXCmFky3oGXGfzxWGtyZNFubTVBieJNyk/wAS+tdX4qkFt4HjhfIedIoVxxycE/oCa8/1+xS2jjl+2sMrtKTMXJ5zxzXiZk6amlb3mepglNx1ehteE7fSNN02K7uDF9pk3EecQTgE4Cj6dKg1TTIdfvpLphJFGFCREErkD0HUDJ6GsGwvIIIlS2iXI6uRyTWpLri6dpd5qF2WNvawvPJtGTtRSxx+ArkrYqU6apRVkdMKChN1G7sYfB8OeLu4/wC+6jk8MQWqmSR2lA7OxP8AOsnTfG+uJ4Zm8Ua7o1lb6C1ib6EW92ZLgDAKKylQuWBHIPHepfBfjCbxZp1+1yLGG4t/KZrSAy+ZCHBYCTzEXPGMMuVPODXO6dVJt7IuNWLaXc7LwrhdPdI3V1SQjYpyU9iPrmtxSD0NedabbtLqN0sUzQXCSbldSQcEZ61rpd39rqlotxetKskixkbVAwTjnA981VPETpO0tV+KIqUr6o7RadUaq69cMvqKfXo0a0a0eaJxtWENMYU803NagiB1qvLHmrxGajdKlxLjIyJoAe1UZoCO1bkkdVJY6zaNoyMGWLIORWx4a8RS6U4t7wtJZHoepj+nt7VBND7VRmi9qcJypu6KlGNRcsj1e1uIbuBJraRZIm5DKeKmryjR9Vu9GnLWzBomPzxN91v8D716Fouu2erJiF9k46xPww+nqPpXp0cRGpp1PLrYeVPVao1a5X/mqf8A3Bv/AGvXVVyv/NU/+4N/7XroOc6qiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKbI6RRs8jKiKMlmOAPxrkNb8ZJGWh0hBNJ085vuD6Dv8Ay+tROpGCvJl06cqjtFHVXl5b2UBmu5kijH8THFcVrHjaSVmh0aLA6efIP5L/AI/lXMXL3eozebfzyTN23HgfQdqlihCjAGK4KuLb0joehSwcY6z1IWWW4lM13K80rdWc5NTBAqknAUcmsjVPEdjYqVhYXM/QLGeAfc1yOoanf6q5EzlYu0a8KPw7/jXMoylqz06eHlLyR02q+J7e2LRWCi4l6b8/IPx7/h+dctdz3OpT+ZeTNIey9l+gpsUCpjecn0q0g7IoH+fStYwUTshCNP4RsNsF64UfmauR+Wh+Vct78mmxwOTls/8AAjtFWMxRL8z59lGBVik7iPK38RCj35NRMrPzsLe78D8qPPZv9RH+IH9ab5UsnMsoQfXJoElYbIi/8tJM+y8ComlRfljUfQCrIigTrukPqxwPyoMqrwoVR6KMUDuVfKlPJCoPVqVYl/iLMfbipGlUe5pNzt9yNj9BQVqX9G1KTTLtXhVAp6jHX8a9T0PUrXVLbzAx3rwyseleNPFOedu36kCtnwnqUum6khknVI2OGwSa1pVHF2exwY3CRrRc4/Ej1x5sDCA49garO7tn5JP++TUwkeSJZI5UKsMggGmb5f76H8DXcfNlCUMTyj/kary8A9fyrQlE3P3T9GqjOXCnIIoAqxcvVieANAWxVOGXMuDW6I92nuQOgoAj+Jc2xNGth0eZpMf7q4/9mrzjxTvbWyrsdoRSo9q734jOH1DQB/syt/6BWD4301pNOgvIk/eoOCO49K+dx7viGe1g7KlHzMCBEihBHU1p2n2e7tpba7RZLeZDHIjdGUjBB+oNc9Z2eq6gB9kt5mTruC8Y+p4q1qOl3WkGGO7uI0uZedjMTgc8kjpyMfnWDoT5ee2hv7WF+W+pe0j4daZbaZcae+p61eaTLbParY3N0Ghhjb+4AoOR2JJx2rR8L+CtP8Nm+mgub29u7tI45Li8kDvsjXaiDaoGAPbJ7k1Z8P3SW9ntupo9+eobj9afqfiSxtY8LKrueABWEqlSV1fcFTindIx57C7m1kf2eF8wxneGOBgEYP61uaT4euEukuNTuEdkOVjjzgH1ya5e11LUFvWvoT5KYKqHXO8Eg8j8B7132j6lHqVosi4SUcPHnJU/4V1UYQkrS3Iqyktti7ErRkjzGKnsanDVDmnA100aUKMeWCsjmk3LVkpNNpM4ozWxFh4NKQDTBShqaYDZEqpKlXWOahcZpSRUXYzpY6pzRZFasi8VUlSs2jVSMeWKodjRuHjZkdTkMpwQa1Xj9qgaGp2NLmlpnjC7tcJqEf2mIcb14cf0P6VZ0vVLTU/iYJbSUMP7GwVPDA+f0IrnZIM9q5d4WTx6GiLI407IKnBH72uuliZR0lqctXDQlrHRn0FRXmmleK9R09lS7/0uAcfOfnA9m/xrtdM8QadqO0QzhJT/AMs5PlbP9fwrsp14T2OOph5091oa1FFFbGAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFR3E8VtC8s8ixxKMlmOAKAJKxdc8RWmlfIT59z2iQ9Pqe1c9rfiyW63QaUGiiPBmIwx+npXNJDyScljySe9cVbFqOkDuo4NvWoWdV1O91iXddvthBysKcKP8T71BHEAAAMVm6rrdnpmUZjLcD/AJZJ1H1PauUv9e1HUFMe8QRN/BFwSPc9a4XzVHdnrUsM2vdVkdXqviCw01jGWM84/wCWcWDj6ntXIarrd/qhZC3kW5/5ZIeo9z3qvbWBOMjaK0I7SOMZbn61pGCR2Qpwp+bMqC1PBCk1dS3Pc4HtV5EL/wCqQsPXoPzp32dRzLJk/wB1P8a0sU53KwWCMdCT9alQSkfuo9q+p+UU/fHD9xVB9TyfzqFp3k+6C3v2oFqx5iP/AC1nAHogzTS1vGflTcfV+ab5TMfnfH05oEMYOSu7/eNACNdlztXJ9hQq3D9Iyo9WOKkMyoMKVX2UVG1yCcDJNAeiF+zt/HKo9lGacsEK9Qzn/aP+FMzM33Y2/EYpwgnb7zog92oD5kqsqfcVF+gprTZ6uab9mUffnz9BSiKBepdvxAoFoRSuMdc1XDgNkdav5t16RKf95iaY1wq/djjH0FBSfkeieAdQkuNLMMpP7vhSfSuiLYY9DXC/D/VCLx7Z+kgyv1rvnA3Z2j8q7qLvFHzOOp8lZ6blWaRfSqUz/KauzhB1jH5VSmVdpwK1OMxZdySb17GtODWFFq0Z6kY5qo0YYt6VAliZbiOMEjewX8zQBt/EGwuJ9M0bULfG63Gx8nGA4XB/MY/GuYuLm/nRLS+uLSGEHPmGVT0/2Qdx6en+Nd/4+KxeG0tgBsmmjiwfQHd/7LXnWvX8FhJHa2MMSzMMswUZFeHmDpxq25bv1PVwam6e+h0C6/FaxpBpNvPLGiBFeUbFYe46n8h0471RNiNRkkmv9rSyAKQo+UAdAB6ViwXRJBZiz+prTF1PHaTPboJJ1RjGh/ibHA/OuOviqtZcsnodNOhClqtytN4SiDfunkUeisQP51asPDEEDhiik+p5P5mvPvhje2OuafaT6n421VvEd7HcJdWAvtnkttcHbDj91sAyGwOR36VrfBdr/UrvX9YOr6pfaA9x9l0xb6cyl1jOHmzgcM3A4HQg1FSlKCld7BGtzWstzd8UJ5MkEafKvmAcemK0rbRba6hDuqkkdxmqvjSEsm5PvDDD6iq1nrEsECnJ2kVjq4qxuaL29xoTC5tGJhB+eIHhh9PX0NdVa3Ed3bRzwnMci7hXEPqN1qwNtboZC3BC/wBfT6muw0m0+wadDbbtxQEsfckk/hkmuzDOVveOesl8y6DTs1HmlzXZc57D80uaZmlp3FYUmmmikNFwI3FV3WrRFRstIpFR0zUZjq0y80wrSLuVGirmHi/4uBj/AKhn/tWuwK1zZXPxD/7hX/tamluJvYtywVWeLHatx4ge1VpYKho1UhdL8Salp2EL/aYB/BKeR9G612Wj+JrDUmWIOYLg9I5OM/Q9DXAyQVXkgB6itqeJnDR6oxqYaFTXZnsVFeY6T4h1DTMJv+0W4/5ZynJA9j2rt9I8QWOp7Vjk8qc/8spOD+Hr+Fd9PEQqepwVcNOnrujXooorc5wooooAKKKKACiiigAooooAKKhurmG0gaa5kWONerMa4zW/E8t2jQ6cGgjPBkPDn6elZVK0aa1NaVGVV6G/rfiK00sFM+fc9okPT/ePauE1O/u9Wn8y7fCZ+WJT8q/h/WqMzwWcTTXMioo5LMa5TV/FMkwMWnAxJ0MrfeP0Hb+f0rzqladbRbHr4bBW+HfudHqOrWWmqRNIDIOkScsfw7fjXJan4gvb8lIibaH+7GfmP1P+GKzIbaSZtzZyTkk9TWlDapHjI5P5mlGmkenGlCnvqyhBaM5yRjP51pQQJEBwM/qasrCQBu/dj0/iqRdsYJX5fViefzrSxUptjUib+LEa+rdfyp+Ik/h3n+8/P6Ug3uMovH95uBTTGv8AGxc+nQUzMa9wz8LlvYdKjIY/fcL7LyafIQBgfkKjCOw6BB/tGkUhuI16KM+rcmmvMAeTk1IYokGZGZz6dBSb3AxDFtHsMUDIwJn+6hA9W4pDBnmWbHstOKyt9+RV+nNHlwjl2dj7nFA7jR9nj/hBPqxzSrcjpEP++B/hSGWCPoiD8M0n2tm4jRj/ALooHa4vmTv92KQ+5GKPLuW67E+rUo+0v0jb8eKPJuD94qv40CE8iQ/enQfQE0G3X+Kdj9BS/Z5P4pkH4mj7Mn8VwPwWgd/MRYIB96SQ/iBSNHbjs5/4FTvIh/56ufoBTWhiHQufxFAF7w5NHb6vbsqtguB971r1raMAiSQfjmvG9MeK21GCRgxVWGea9djP7pSjtgjPPNdWHejR4mbR9+L8iSQHHEit9Riq0q5U8YqYMSPmwf0qGZgEJ6V0nkGeV2mrdsoSWCY9EkU/rVNW3yVqCEmzagCX4kSnOjwjo87MfwX/AOvXjs1z5uo3NxIckuQPpXqPxPuWT/hHyi7nYyMFHf5V/wAa4fwlpEba+q6qoRUyyRydJW7D0464rwcYubENeh7OEfLRTKlimpXKhrWxnkQ9HWMkfnWnDfXNjdC3vbeRJQA23bng/SvShgDA6Cua8QaPdS6gNQ04o8uwJJE5xux0IPTP1rKphko6as0jXu7MlsLeyl8ydbSFZZV2yOYgGcehOMn8auRJDawrHCkcMSDCogCgfQCua+16uuVbTrkEeiZH5ikuo9eks5JLbTy8oxtjklVN3Pr29ea4vY1G7WNeaK1uSa/dxO2AQcfpWvpVgkOnWhks4Gfy13K0Q3A478da5nTrfXYZFmvPDf2iYHIH2+MIp+mOT9fyrbOseIf+hY/8qEf+FbvAKpC039zMZV1sjo4ZbVk8sxrER/dG0ilOAcA5HrXMtqviBiM+Fgcet/H/AIUv9r+Iv+hY/wDKhH/hVYXBzoN80roylOL2Okpea5r+1/EP/Qsf+VCP/Ck/tfxD/wBCx/5UI/8ACu3lYuZHTZpQa5n+1/EP/Qr/APlQj/wpf7X8Q/8AQr/+VCP/AAosxXR02aSua/tfxF/0LH/lQj/wo/tfxD/0LH/lQj/wp2YXR0ppprnDq/iL/oWP/KhH/hSf2v4i/wChY/8AKhH/AIUcrC6OhYVGy1gnVvEP/Qsf+VCP/CmnVvEP/Qsf+VCP/CjlY+ZG9iubx/xcX/uFf+1qk/tXxD/0LH/k/H/hUekW+q3XiuTU9R01bGBbL7Mo+0LKWbzN2eOgxTStcG7nRlaYyZFWMUbaRVzPki9qrSQ+1azR1XkiqWilIyHi9qgeLn0rWki9qrPHUGiZd0jxNfaeVScm5t+4c/MPof8AGu10vWrHUwPs0wEp6xPww/Dv+FebvFUDRlWDISrDkEHBFdFLFSho9Uc9XCwqarRnsNFcLo3iye2RYtRRp0HAlX74+vrXZ2d3BewiW2lWRD3B6fX0r0adaNT4TzqtGdN+8T0UUVqZBRRUdxNFbxGSd1RB1ZjgUbBuSVh654ittNJhj/f3X/PNTwv+8e30rD13xLLdh7fTt0MJ4aXozfT0H61y88tvYwtLcSLGndmPU/1rhrYtL3YHfQwblrP7i/qN9danMJbyTOPuovCr9BXOa3r9vpwaKLE11/cB4X/eP9Kwta8TTXbNDYFoIOm8cO/+A/WsWGEdX/KuRRcneR7dHCqK977h97d3eqziS5fdj7qjhV+gqWC1VMF+TTw6oMKOfQUK46sRn0rVKx1bKyLkI6Y+VfWpt4jyV+X1Y9arROX6YA9TUy+WvJO4+ppmbQ5C0nI4X+8alBROep9W5qPLMOOB6mm5UH+8fU0CJDK8nKgkf3jwKYT/AHmLfTgUx37saYJNxxGrOfYUAkS7z0UBR7UBscnmmLFK33mVB+ZqRYY15bc5/wBo8flQGhGZwGwgy3sMmjZcP1UIPVzU+4KMLhR6Dio2lGcZGfSgPQjaD+/OT7IuP503yIRyVZv95qkO49EY/hj+dIVkP8Cj6tQO7GoFU/u4kB9QtPLzk4BQD3agRv3kjX8CaURD+K4/75WgNBuyQ/enUfQE0nkqfvTufouKk8qLvPKfoBR5cP8AfmP4igLkRhi/vyn8RSGGLPBf8WqYxwf3pj+NNMUP96X86AuMEUXcP/31SNDD/wBNP++qcYY+zyj8qaYVxxK/4igdyuyxq4Pz4+teq+F7hbzRoTvJZBsJPtXlbxn/AJ6L+Ir0HwMGj0s4w6s2cqc4rfDv3jz80SdFPzOpMbAZAyPaqV4mYyR1q5FKp4zz6U2cbkNdh88c/ZybbkKx4Jrr40j+wsf9muQu7Zg5ZQc+1TQajdRxeXICy9KAE8esH1Lwz5h+QQMT/wCO1h+Mbm3N1Glm+6XIK7OoPbH412viLQbfXNH02aWaWGSCLClMcggdfyrL0nw1p+mzCdQ8845Ekpzj6DpXh4ui5VnI9bDVEqaXY3VLbF343Y5+tBNNLU0mrbEkOJpKTNITUNlWFJpabS9qQAaQ0UhNAxaKSkoAkopoNOpiCkzRmmmgB4NA5poNOFMAIpCKfQBQAzFG2pMCk20xXGbaMVJijFMCPbUbpU+KQigCjJHVWSOtN1qu6VDRomZzJUTJV9o+elMMXtU2LuUPJyeK0dKM1rcLLAxRvbofrRHBk9K1LS26cVtSi73RlUkrWZ0Onaj56hZl2v6joa0ayLKHaRxWpGMV6lNtrU8uoknoR3M/kxkgZI9a4XWrmW6nJlcsB0HYfhXZX65V65C7i3SN2Fc+JvL3TowzjH3jl9V1JbJMRxtPOekadvqe1cVfQatqtwZbiN229FxhUHsK9TFnGowiKD9KmjtY412qPck96zhQgup3QxzpbQ1PHf7PnizuiYY6nFHlSAZIIFexfZIHJEkaso7EdT71FJplo5/1EeT0+WtPYLozRZt/NE8hKvj5UI/rTki2fNLyfSvWm0exUf6lWbuxqrceHbO4Q712DsFH86Pq8ilm1N7o8xMrMeBhfWlSUA9cn1NdtfeEI2UmOc+wIrn7vwtfRgskZMY/iHf6VnKlKPQ6qeMoVNpGcbkAfM2TSebI5wq7R6tTHsZ7cnMTAjuRzUCtIxO1SSOpNQdKs9i8iJnMh3n36VP56KMZAHoKz1Ix+8YsfQcCpUlCfdAWgTiW97t91No9W4phVyfmk4/2RUC3G84QFz7VIBK3Uog9+TQK1iUBB1Xcf9o5oM20YBCj0Xio/KU/ed2+nAp6pGv3Y1/HmgWgwyqTwSf1pwLt92Nz+FS+Yw6HA9hSbnb+I/nQAmyQDJTb/vEUBGPeMf8AAv8A61LtJ6kUnluTwy4+hoC4eW3/AD1jH50hhPaZPyNTJbsf4/8Ax3/69SrZsf4//HaLi5il5D/89l/Kl+zuekqH61oLYt/eH/fNPWxf1U/hSuLnM4Wkx6SR/nSG3nHZT9DWwtg/90H6GniwbupFLmRPtDCe1mYfcH511fgKV4POgkVwPvDiqP2DPrWt4et3t79WBOMEGrhU5ZXMMU1UpOJ1qsknXBP60jIexyKacN94DPrSg9s/nXQ654XsSu8eW5FMeFfSrD9aYTS9sP2RqtMBpMKeiAVnb6a8v7gLUKtXFVnzM7KcOVFkN60oNQqakU8Vlc0sPopBS0hCilptOpoBDTe9OIpKYAKKKKAFFLSCloENNJSkUYphcBT1pAKcKBXFpRRRmmIUUtIKWgApMUtIaYCYopaMUhjCM1GyVPijbRYLlXy6cIcnpVtY81PHDntVRhcTnYqw23PStO2gxjipIYOnFXI48V2UqdjlqVLjoUxVhajAxUi11LQ5mQXC7ga5++tsOTiulYdapXUIYGsa0OZGtKfKzmvLwelMZea0pocE1UePmvNlFo74yTK+KULTytGKhNoppMbtFLtzTqUVrGvNdTKVKD6EXl5bJGQO1I6k/eqwKMA1vHFy6mTwy6GfJZQyczIH9Fxx+NY+o6BZzqf3ezPQIP6V1BQEU3y8cjrWyrwn8SFGNWk7wZ5reeELlMvGcL2Xq1YV3YTWpIlhbHq1exPF61Tu7KKZCskYfPbFN0oS1izrp5nUg7VFc8gR8cdKmSTHeuxv/Bgdmkhk8sf3ByayT4Znik2tGzD1J61hKDjuenTxdKqrpmQJ0HVhUiFn/wBXG7fRTXS2Xhtlx+7VfwrZg0EKAWrPmQSrwRw6W9054gYf7xxVmLTLpuuwfjXdJpUafw1Itoifw1LmYvE9jjotGmI5dfyNW49HcdWH/fNdUsKjtUnlr6UuczeIkznItLA6n9KnXTwO4/KtooKTaKXMR7VsylsMelSLZf7IrSwKBip5mLnZQFp7U4W3tV7iilzBzMpC3HcCpreEJIGAx9Klp60ricromFLmowaXNPmZnyoUtUZNKxphNPnYciEY8Ui0hpUqHqWiVOamWmRjiplFFhMSlpcUYpkiCnUAUtAhDTTTzzTKYwFLSCjPFMBaN1MLUmaQhxalFMHJqQCgBRThSAUtMTFoxSUoNUhCg06kpaGAUUUoFIBMUoFPC09UqkhXGKme1SrH7VKkdWEirWMLmcpkMcVWoovapEjqdExXTCmc8piRpgVKBQBTgK3SsYt3AChetLQBg1QhGqNxkVKaawpMEZ1xFmqEkPNbUi5FVJI65alO50wnYyHixUTJitR4vaoHhrllTOiMygVoAqy0WKjK4rNxsXzXGAUuKXFFIdwoopM0AKabsGeOCaXNGapScdiXFPcb5YHWlMasOQKXNOHSm5uW4lFLYaqKvRaVsdqWmtxUlET1WkqzJ0qrJUstDM0bqYTSbqRViQmmk03NITTAfmjNMpw5pDHZ4opKKQBmnKaZS0AS0U1TmlNACMaYTSk0wmgYhNPj61Gakj6igGW4xU6rUUPNWVHFWkZNjMUYqUjimkU2ibkeKKcRTaRQhqM09qY1IaEzikJoNNY4FAxpalU1Ex5p6UATIKlxTYxxUmKaJuIKU0UuKZI2lFGOaUUIBRTsUiipFU1dhMbinqtSpHUyRe1VGFyHIiSOrCR1LHFU6JW8aZjKZGkdTolOVakAreMLGLkIq08CjtS1qkQwoptPUcc0xAOtLSDqaWmITvSGlIPWm5pDGsM1GyZqam9alq5SZWaOoXiq8VprJWbgWpmY8XtVd461XjqB4qwlSNY1DMZKjIrReGoXi9qxdNo1UykaaastFio2SsnFmiaIaM04rSEYqdShKeKZinqKEA6mkU8DikIpiIHFVZRVxxVaQVLLRTamZqWQVAxpFjs0uajBpwphYeKcKaKWkMdSnpSZoNIQCl7UlApgxynFKzUzNITQCAmoyaCaYTSKsOzzU0fWqwPNTxHmgTNCCra1Tt6uLWsTGQ40008001ViCM0009qYahlIa1RtUhpjdKRaIzUbmpG6VDJUjIyeami5qCp4RTQMtxjin0IOKkCVaRk2MxS4NSqlSLFVKNyXIr7DThHVtYalSD2rSNNkuZUSI1Yjhq0kI9KnWLFbRpGUqhWSKpljxU4SnBa2ULGTmRqlPAp2KWrSIbEAp1AFLVCCkNLSYoARRk1JSAYFA5NNaCYtFFFMQ3JBORxTsA0hbBxigMDSGLQQDRRTENK+lNIqSgjNKw7kJFNKVIyke9NzUtFJkLR1G0PtVrrRgVDgmUpNFB4PaoHg9q1ClMaPNZuki1UMh4faomi9q1miqJoaxlSNY1DKMZ9KcENXmh9qTyqz9kX7QqbTTWBq55VNaI0nBjUyg61BItaLxH0qCSE4rNwZopIyZVqnJxWtNCeaoTRGp5WaKSKm7mpFamGMinohpWKuSKadmmhTS4osFxwNKDTQDTgDmlYBRRShaXbRYBlNPSpMUxhRYZC1MY1K4qJgaQ0ANWIuoqsoNWYhyKEDNC36VcTpVS3HFXUHFbRRzyYvakI5p+KMVViLkLUwipytMKVLRSZCRTSOKs+X7UeUTS5WVzFJl4qF1NaRhNR/Zie1NQYc6KCRknpVqGL2q1HanPSrsNtjtWkaTIlVRVihPpVhYfarqQY7VMsIreNE55VSmkHtUyQVbWMCnha2VJIydQrrEKeIxU4WjFWo2IcmRhRTgKdRVWFcbS0lGaBBRRmkzSHYdmjNNzQDTuFh1OApFGaceKaEIx7UAYoAxyaAcmgBaKKKYhDg0hX0pcc0tIBmSKcGzS0mMHigYtFFFMQU1kB9qdRQBCVK/SjNTU0qD7VPKVcZgntSEVKowMUtFhXICKYUqyVB7UhT0pOJSkVTHSeWKslDSFalwGpFby6QxVZ20baXIPmKTQg1G0A9K0NtNKVLpopTZkyW2e1U5rPrxXQNH7VE8IPao9ki1VZzT2XtTRZ47V0LW49KT7OPSpdFFqsYH2Q+lNNqfSuh+zD0pDaj0pOgNVjnxbH0o+zmt77L7Uv2UelT7AftjCMB9KQwH0re+y+1J9kHpS9gP2xgeQfSkNufSt82ftSfY/aj2DH7c51rc+lMa3PpXS/Yh6Un2EelL6uw9ujmltjnpViG2OelbwsR6VKlmB2prDieIMyCAjtVpYq0EtgO1SiEelaRoWMnWuZvkmlEPtWl5PtR5QqvYk+1M7yfagQVpeV7UeX7U/Yi9qZ4gpwt/ar4SnBBVKkhOoyj9nGOlOFuPSru0UbapU0TzsrLAB2qZYwO1SYoq1FEuTECinYopadiRaKBRTAKQ0tGKAEpKcBS4oAjwe1G0+lSUUWC5HsagIfWpKKLILjPL96UIPenUUWQXCjFFFMQEZoAAoooAKKKKADNFJgZpcUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACFRSFadRSsAzFJipMUmKLDuMIppWpdoo2ilYLkBSjYKn2ijaKLDuQhBS7Kl2ijaKdhXItgpdgqXAowKLBci2CjYKlwKKLBci2CjYKlwKMCiwXItg9KNgqXAowKLBcj2igKKkxRRYLjdtGKdRRYLjcUYp1FFgG49qMU6iiwXGYop9FFguR0dakoosFxm00oX3p1FFguJtFLgUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6210=[""].join("\n");
var outline_f6_4_6210=null;
var title_f6_4_6211="Mandible fracture epidemiology";
var content_f6_4_6211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Mandible fracture epidemiology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mandible fractures: sites and incidence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harwood-Nuss, A, Wolfson, AB, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6211=[""].join("\n");
var outline_f6_4_6211=null;
var title_f6_4_6212="High cholesterol and lipids (hyperlipidemia)";
var content_f6_4_6212=[" <h1 id=\"patTopicTitle\">",
"  Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/4/6212/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/4/6212/contributors\" id=\"au5541\">",
"       Robert S Rosenson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/4/6212/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/4/6212/contributors\" id=\"se212\">",
"       Mason W Freeman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/4/6212/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/4/6212/contributors\" id=\"de6672\">",
"       David M Rind, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?6/4/6212?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Hyperlipidemia refers to increased levels of lipids (fats) in the blood, including cholesterol and triglycerides. Although hyperlipidemia does not cause you to feel bad, it can significantly increase your risk of developing coronary heart disease, also called coronary artery disease or coronary disease. People with coronary disease develop thickened or hardened arteries in the heart muscle. This can cause chest pain, a heart attack, or both. Because of these risks, treatment is often recommended for people with hyperlipidemia.",
"    </p>",
"    <p>",
"     This topic reviews the risk factors for coronary disease, the types of lipids, and when cholesterol testing should begin. The treatment of high cholesterol is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=see_link\">",
"      \"Patient information: High cholesterol treatment options (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      OTHER RISK FACTORS FOR CORONARY DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     In addition to hyperlipidemia, there are a number of other factors that increase the risk of coronary disease and its complications.",
"    </p>",
"    <p>",
"     The following are coronary disease-risk equivalents; people with these medical problems are thought to be at similar risk for complications of coronary disease as people with known coronary disease.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Many patients with diabetes mellitus, type 1 and 2 (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"        \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"        \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Symptomatic carotid artery disease (eg, stroke or transient ischemia attack) (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?20/18/20772?source=see_link\">",
"        \"Patient information: Transient ischemic attack (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"        \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Peripheral artery disease (eg, claudication) (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=see_link\">",
"        \"Patient information: Peripheral artery disease and claudication (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Abdominal aortic aneurysm (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?33/62/34787?source=see_link\">",
"        \"Patient information: Abdominal aortic aneurysm (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Kidney disease (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"        \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Other factors that increase the risk of coronary disease include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cigarette smoking",
"      </li>",
"      <li>",
"       Hypertension (blood pressure",
"       <span class=\"nowrap\">",
"        &ge;140/90",
"       </span>",
"       or use of blood pressure medication) (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"        \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Family history of coronary disease at a young age in a first degree relative (parents and siblings). In males: first degree relatives under 55 years; in females: first degree relative under 65 years",
"      </li>",
"      <li>",
"       Gender: Men have a higher risk of coronary disease than women at every age",
"      </li>",
"      <li>",
"       Age: There is an increasing risk of coronary disease with increasing age",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      LIPID TYPES",
"     </span>",
"    </p>",
"    <p>",
"     The term lipids includes cholesterol and triglycerides. There are many different types of lipid (also called lipoproteins). Blood tests can measure the level of your lipoproteins. The standard lipid blood tests include a measurement of total cholesterol, LDL (low density lipoproteins) and HDL (high density lipoproteins), and triglycerides.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Total cholesterol",
"     </span>",
"     &nbsp;&mdash;&nbsp;A high total cholesterol level can increase your risk of coronary disease. However, decisions about when to treat high cholesterol are usually based upon the level of LDL or HDL cholesterol, rather than the level of total cholesterol.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A total cholesterol level of less than 200",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (5.17",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"       is",
"       <strong>",
"        normal",
"       </strong>",
"       .",
"      </li>",
"      <li>",
"       A total cholesterol level of 200 to 239",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (5.17 to 6.18",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"       is",
"       <strong>",
"        borderline high",
"       </strong>",
"       .",
"      </li>",
"      <li>",
"       A total cholesterol level greater than or equal to 240",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (6.21",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"       is",
"       <strong>",
"        high",
"       </strong>",
"       .",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The total cholesterol level can be measured any time of day. It is not necessary to fast (avoid eating for 12 hours) before testing.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      LDL cholesterol",
"     </span>",
"     &nbsp;&mdash;&nbsp;The low density lipoprotein (LDL) cholesterol (sometimes called \"bad cholesterol\") is a more accurate predictor of coronary disease than total cholesterol. Higher LDL cholesterol levels increase your risk of coronary disease.",
"    </p>",
"    <p>",
"     Most healthcare providers prefer to measure LDL cholesterol after you have not eaten (fasted) for 12 to 14 hours. A test to measure LDL in people who have not fasted is also available, although the results may differ slightly.",
"    </p>",
"    <p>",
"     You should know your LDL cholesterol level and your LDL goal. This goal depends upon several factors, including your history of coronary disease or coronary disease-risk equivalents and your 10-year risk score of developing coronary disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Ten year risk of developing coronary disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;The 10-year risk score is based on information from the Framingham Heart Study, a large study that has followed participants, as well as their children and grandchildren, for greater than 50 years. The 10-year risk can be calculated for women (",
"     <a class=\"calc calc_patient\" href=\"UTD.htm?15/19/15679?source=see_link\">",
"      calculator 1",
"     </a>",
"     ) and for men (",
"     <a class=\"calc calc_patient\" href=\"UTD.htm?15/14/15599?source=see_link\">",
"      calculator 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Triglycerides",
"     </span>",
"     &nbsp;&mdash;&nbsp;High triglyceride levels are also associated with an increased risk of coronary disease. Triglyceride levels are divided as follows:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Normal - less than 150",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (1.69",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"      </li>",
"      <li>",
"       Borderline high - 150 to 199",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (1.69 to 2.25",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"      </li>",
"      <li>",
"       High - 200 to 499",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (2.25 to 5.63",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"      </li>",
"      <li>",
"       Very high - greater than 500",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (5.65",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Triglycerides should be measured after fasting for 12 to 14 hours.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      HDL cholesterol",
"     </span>",
"     &nbsp;&mdash;&nbsp;Not all cholesterol is bad. Elevated levels of HDL cholesterol actually lower the risk of heart disease. In fact, a very high HDL (greater than or equal to 60",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     or 1.55",
"     <span class=\"nowrap\">",
"      mmol/L)",
"     </span>",
"     is considered a negative risk factor for coronary disease (removes one risk factor). On the other hand, treatment is sometimes recommended for people with low levels of HDL cholesterol (less than 40",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     or 1.03",
"     <span class=\"nowrap\">",
"      mmol/L),",
"     </span>",
"     particularly if they already have coronary disease.",
"    </p>",
"    <p>",
"     Similar to total cholesterol, the HDL-cholesterol can be measured on any blood specimen. It is not necessary to be fasting.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2401344799\">",
"     <span class=\"h2\">",
"      Non-HDL cholesterol",
"     </span>",
"     &nbsp;&mdash;&nbsp;Non-HDL cholesterol is calculated by subtracting HDL cholesterol from total cholesterol. Since total cholesterol and HDL cholesterol can be measured without fasting, so can non-HDL cholesterol. Non-HDL cholesterol is a good predictor of cardiovascular risk and is a better predictor of risk than LDL cholesterol in people with type 2 diabetes and in women.",
"    </p>",
"    <p>",
"     An appropriate non-HDL cholesterol goal can be calculated by adding 30",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (0.78",
"     <span class=\"nowrap\">",
"      mmol/L)",
"     </span>",
"     to your LDL cholesterol goal. As discussed, the LDL cholesterol goal depends on a number of factors. (See",
"     <a class=\"local\" href=\"#H5\">",
"      'LDL cholesterol'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      WHEN SHOULD I HAVE MY CHOLESTEROL LEVEL TESTED?",
"     </span>",
"    </p>",
"    <p>",
"     Many expert groups have guidelines for cholesterol screening. The guidelines differ in their recommendations about when to start screening, how frequently you should be screened, and when to stop.",
"    </p>",
"    <p>",
"     One expert group, the United States Preventive Services Task Force recommends the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Lipid screening should start at age 35 in men without other risk factors for coronary disease and at age 20 to 35 in men with risk factors. These include men with diabetes, a family history of heart disease in a close male relative younger than age 50 or a close female relative younger than age 60, a family history of high cholesterol, or a personal history of multiple coronary disease risk factors (eg, smoking, high blood pressure).",
"      </li>",
"      <li>",
"       Lipid screening should definitely start at age 45 and perhaps at age 20 in women with other risk factors for coronary disease. No recommendation for or against screening was made for women without risk factors for coronary disease. UpToDate authors believe that even low risk women should be screened starting at age 45.",
"      </li>",
"      <li>",
"       Those at risk for coronary disease should be treated based upon the results of their screening test.",
"      </li>",
"      <li>",
"       Screening should include total cholesterol and HDL-cholesterol levels and can be measured anytime (with or without fasting).",
"      </li>",
"      <li>",
"       The optimal time interval between screenings is uncertain; reasonable options include every five years, with a shorter interval for those with high-normal lipid levels and longer intervals for low-risk individuals with low or normal levels.",
"      </li>",
"      <li>",
"       There is no recommendation to stop screening at a particular age.",
"      </li>",
"      <li>",
"       Screening may be appropriate in older people who have never been screened, although screening a second or third time is less important in older people because lipid levels are less likely to increase after age 65.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      HIGH CHOLESTEROL TREATMENTS",
"     </span>",
"    </p>",
"    <p>",
"     The treatment options for people with high cholesterol and lipids are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=see_link\">",
"      \"Patient information: High cholesterol treatment options (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287448393\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2374856895\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/5/23635?source=see_link\">",
"      Patient information: Atherosclerosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=see_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/40/22144?source=see_link\">",
"      Patient information: The ABCs of diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/14/38114?source=see_link\">",
"      Patient information: Nonalcoholic steatohepatitis (NASH) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/37/36435?source=see_link\">",
"      Patient information: Medicines after an ischemic stroke (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/6/37987?source=see_link\">",
"      Patient information: Heart attack recovery (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/27/21940?source=see_link\">",
"      Patient information: Medicines after a heart attack (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21156?source=see_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/40/39554?source=see_link\">",
"      Patient information: Lowering the risk of having another stroke (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/54/7012?source=see_link\">",
"      Patient information: Coronary heart disease in women (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/56/24450?source=see_link\">",
"      Patient information: Can foods or supplements lower cholesterol? (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2374857073\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=see_link\">",
"      Patient information: High cholesterol treatment options (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/18/20772?source=see_link\">",
"      Patient information: Transient ischemic attack (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=see_link\">",
"      Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/62/34787?source=see_link\">",
"      Patient information: Abdominal aortic aneurysm (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=see_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=see_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=see_link\">",
"      Screening guidelines for dyslipidemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43621?source=see_link\">",
"      Secondary causes of dyslipidemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10329?source=see_link\">",
"      Treatment of drug-resistant hypercholesterolemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10760?source=see_link\">",
"      Treatment of dyslipidemia in the older adult",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cholesterol Education Program of the National Heart, Lung, and Blood Institute of the NIH",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/chd\">",
"      www.nhlbi.nih.gov/chd",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/other.cfm\">",
"      www.hormone.org/public/other.cfm",
"     </a>",
"     , available in English, Spanish, and Portuguese)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Framingham Heart Study",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.framingham.com/heart/\">",
"      www.framingham.com/heart/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?6/4/6212/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?6/4/6212?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6212/abstract/1\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6212/abstract/2\">",
"      Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f6_4_6212=[""].join("\n");
var outline_f6_4_6212=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           OTHER RISK FACTORS FOR CORONARY DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           LIPID TYPES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           WHEN SHOULD I HAVE MY CHOLESTEROL LEVEL TESTED?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           HIGH CHOLESTEROL TREATMENTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        CALCULATORS",
"       </h1>",
"       <div id=\"relatedCalculators\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"UTD.htm?15/19/15679?source=related_link\" title=\"calculator 1\">",
"           Calculator: 10 year risk of developing cardiovascular disease in women (Patient information)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"UTD.htm?15/14/15599?source=related_link\" title=\"calculator 2\">",
"           Calculator: 10 year risk of developing cardiovascular disease in men (Patient information)",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f6_4_6213="Bisacodyl: Drug information";
var content_f6_4_6213=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bisacodyl: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/49/15124?source=see_link\">",
"    see \"Bisacodyl: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/56/42883?source=see_link\">",
"    see \"Bisacodyl: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alophen&reg; [OTC];",
"     </li>",
"     <li>",
"      Bisac-Evac&trade; [OTC];",
"     </li>",
"     <li>",
"      Biscolax&trade; [OTC];",
"     </li>",
"     <li>",
"      Correctol&reg; Tablets [OTC];",
"     </li>",
"     <li>",
"      Dacodyl&trade; [OTC];",
"     </li>",
"     <li>",
"      Doxidan&reg; [OTC];",
"     </li>",
"     <li>",
"      Dulcolax&reg; [OTC];",
"     </li>",
"     <li>",
"      ex-lax&reg; Ultra [OTC];",
"     </li>",
"     <li>",
"      Femilax&trade; [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Bisacodyl [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Stimulant Laxative [OTC];",
"     </li>",
"     <li>",
"      Veracolate&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Bisacodyl&reg; [OTC];",
"     </li>",
"     <li>",
"      Bisacodyl-Odan [OTC];",
"     </li>",
"     <li>",
"      Bisacolax [OTC];",
"     </li>",
"     <li>",
"      Carter's Little Pills&reg; [OTC];",
"     </li>",
"     <li>",
"      Codulax [OTC];",
"     </li>",
"     <li>",
"      Dulcolax&reg; [OTC];",
"     </li>",
"     <li>",
"      PMS-Bisacodyl [OTC];",
"     </li>",
"     <li>",
"      ratio-Bisacodyl [OTC];",
"     </li>",
"     <li>",
"      Silver Bullet Suppository [OTC];",
"     </li>",
"     <li>",
"      Soflax [OTC];",
"     </li>",
"     <li>",
"      The Magic Bullett [OTC];",
"     </li>",
"     <li>",
"      Woman's Laxative [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F141482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Laxative, Stimulant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F141446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Relief of constipation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     5-15 mg as single dose (up to 30 mg when complete evacuation of bowel is required)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Rectal:",
"     </i>",
"     Suppository: 10 mg as single dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F141462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/56/42883?source=see_link\">",
"      see \"Bisacodyl: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Relief of constipation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Children &gt;6 years: 5-10 mg (0.3 mg/kg) at bedtime or before breakfast",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Rectal (suppository):",
"     </i>",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;2 years: 5 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;2 years: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F141447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use with caution in patients with impaired renal function.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F141427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, rectal [enema]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Bisacodyl: 10 mg/30 mL (37 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal: 10 mg (12s, 50s, 100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bisac-Evac&trade;: 10 mg (8s, 12s, 50s, 100s, 500s, 1000s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biscolax&trade;: 10 mg (12s, 100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dulcolax&reg;: 10 mg (4s, 8s, 16s, 28s, 50s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, oral: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doxidan&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Stimulant Laxative: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, enteric coated, oral: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alophen&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bisac-Evac&trade;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Correctol&reg; Tablets: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dacodyl&trade;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dulcolax&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ex-lax&reg; Ultra: 5 mg [contains sodium 0.1 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Femilax&trade;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Veracolate&reg;: 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F141416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes enema",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F141430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer tablet with a glass of water on an empty stomach for rapid effect. To protect the enteric coating, tablet should not be administered within 1 hour of milk, any dairy products, or taking an antacid.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F141428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of constipation; colonic evacuation prior to procedures or examination",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F141486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxidan&reg; may be confused with doxepin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dulcolax&reg; (bisacodyl) may be confused with Dulcolax&reg; (docusate)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F141481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1% (Limited to important or life-threatening): Electrolyte and fluid imbalance (metabolic acidosis or alkalosis, hypocalcemia); mild abdominal cramps, nausea, rectal burning, vertigo, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F141433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bisacodyl or any component of the formulation; abdominal pain or obstruction, nausea, or vomiting",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F141423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F141440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Milk or dairy products may disrupt enteric coating, increasing stomach irritation.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14206265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma concentrations of BHPM (the active metabolite of bisacodyl) are low (median: 61 ng/mL; range: 21-194 ng/mL) following doses of 10 mg/day for 7 days (Friedrich, 2011). Although not first choice for the treatment of constipation in pregnant women, short-term use of stimulant laxatives is generally considered safe in pregnancy; long-term use should be avoided (Cullen, 2007; Prather, 2004; Wald, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13736959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neither bisacodyl nor its active metabolite (BHPM) were detectable in breast milk following administration of bisacodyl 10 mg once daily for 7 days to eight lactating women (limit of detection: 1 ng/mL) (Friedrich, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F141435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To protect the enteric coating, tablet should not be taken within 1 hour of milk, any dairy products, or taking an antacid. Should be administered with a glass of water on an empty stomach for rapid effect.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F141434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Enema",
"     </b>",
"     (Fleet Bisacodyl Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/30 mL (37 mL): $2.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Bisac-Evac Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (50): $11.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Bisacodyl Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (12): $2.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Dulcolax Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (16): $14.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Alophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $5.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Bisac-Evac Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (25): $3.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Bisacodyl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $1.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Carters Little Pills Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (25): $2.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Correctol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $4.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Dulcolax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (25): $5.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Ex-Lax Ultra Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (24): $5.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Feenamint Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (10): $1.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Fleet Laxative Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (24): $3.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (GNP Bisa-Lax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $7.99",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F141436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alaxa (IT);",
"     </li>",
"     <li>",
"      Alsylax (CN);",
"     </li>",
"     <li>",
"      Anan (JP);",
"     </li>",
"     <li>",
"      Anulax (EC);",
"     </li>",
"     <li>",
"      Atzirut X (IL);",
"     </li>",
"     <li>",
"      Bekunis B (LU);",
"     </li>",
"     <li>",
"      Bicolax (ID);",
"     </li>",
"     <li>",
"      Bioyl (TW);",
"     </li>",
"     <li>",
"      Bisacod (TH);",
"     </li>",
"     <li>",
"      Bisakodils (EE);",
"     </li>",
"     <li>",
"      Bisalax (AU, BG);",
"     </li>",
"     <li>",
"      Bisco (PH);",
"     </li>",
"     <li>",
"      Buscolax (PH);",
"     </li>",
"     <li>",
"      Contalax (FR);",
"     </li>",
"     <li>",
"      Correctol (HK);",
"     </li>",
"     <li>",
"      Cosadin (PH);",
"     </li>",
"     <li>",
"      Custodiol (ID);",
"     </li>",
"     <li>",
"      Dissilax (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Dulco Laxo (ES);",
"     </li>",
"     <li>",
"      Dulco-lax perles (GB);",
"     </li>",
"     <li>",
"      Dulcolan (VE);",
"     </li>",
"     <li>",
"      Dulcolax (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CO, CR, CY, DE, DK, DO, EC, EG, ET, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, IN, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PT, PY, QA, RU, SA, SC, SD, SE, SL, SN, SR, SV, SY, TH, TN, TT, TW, TZ, UG, UY, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Fenolax (CZ);",
"     </li>",
"     <li>",
"      Gencolax (TH);",
"     </li>",
"     <li>",
"      Johnlax (TW);",
"     </li>",
"     <li>",
"      Lax-Tab (AU, NZ);",
"     </li>",
"     <li>",
"      Laxacod (ID);",
"     </li>",
"     <li>",
"      Laxadin (IL);",
"     </li>",
"     <li>",
"      Laxadyl (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Laxana (ID);",
"     </li>",
"     <li>",
"      Laxans-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Laxatin (TW);",
"     </li>",
"     <li>",
"      Laxcodyl (TH);",
"     </li>",
"     <li>",
"      Laxitab 5 (TH);",
"     </li>",
"     <li>",
"      Longshutong (CL);",
"     </li>",
"     <li>",
"      Medesup (ES);",
"     </li>",
"     <li>",
"      Moderlax (PT);",
"     </li>",
"     <li>",
"      Perilax (DK, ZA);",
"     </li>",
"     <li>",
"      Purgo-Pil (LU);",
"     </li>",
"     <li>",
"      Pyrilax (PL);",
"     </li>",
"     <li>",
"      Satolax-10 (JP);",
"     </li>",
"     <li>",
"      Stadalax (CZ);",
"     </li>",
"     <li>",
"      Suben (TW);",
"     </li>",
"     <li>",
"      Tirgon N (LU);",
"     </li>",
"     <li>",
"      Toilax (DK, FI, IE, NO, SE);",
"     </li>",
"     <li>",
"      Vacolax (TH);",
"     </li>",
"     <li>",
"      Vesilac (PH);",
"     </li>",
"     <li>",
"      Zu Zu Ton (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F141419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates peristalsis by directly irritating the smooth muscle of the intestine, possibly the colonic intramural plexus; alters water and electrolyte secretion producing net intestinal fluid accumulation and laxation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F141432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 6-10 hours; Rectal: 0.25-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : BHPM: 289 L (after multiple doses) (Friedrich, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: BHPM: ~8 hours (Friedrich, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Bisacodyl is metabolized to an active metabolite (BHPM) in the colon; BHPM is then converted in the liver to a glucuronide salt (Friedrich, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, rectal: Systemic, &lt;5% (Wald, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: BHPM: Urine, bile (Friedrich, 2011)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cullen G and O'Donoghue D, \"Constipation and Pregnancy,\"",
"      <i>",
"       Best Pract Res Clin Gastroenterol",
"      </i>",
"      , 2007, 21(5):807-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6213/abstract-text/17889809/pubmed\" id=\"17889809\" target=\"_blank\">",
"        17889809",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedrich C, Richter E, Trommeshauser D, et al, \"Absence of Excretion of the Active Moiety of Bisacodyl and Sodium Picosulfate Into Human Breast Milk: An Open-Label, Parallel-Group, Multiple-Dose Study in Healthy Lactating Women,\"",
"      <i>",
"       Drug Metab Pharmacokinet",
"      </i>",
"      , 2011, 26(5):458-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6213/abstract-text/21697613/pubmed\" id=\"21697613\" target=\"_blank\">",
"        21697613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prather CM, \"Pregnancy-Related Constipation,\"",
"      <i>",
"       Curr Gastroenterol Rep",
"      </i>",
"      , 2004, 6(5):402-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6213/abstract-text/15341717/pubmed\" id=\"15341717\" target=\"_blank\">",
"        15341717",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wald A, \"Constipation, Diarrhea, and Symptomatic Hemorrhoids During Pregnancy,\"",
"      <i>",
"       Gastroenterol Clin North Am",
"      </i>",
"      , 2003, 32(1):309-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6213/abstract-text/12635420/pubmed\" id=\"12635420\" target=\"_blank\">",
"        12635420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8815 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-D8E5382BBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6213=[""].join("\n");
var outline_f6_4_6213=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141442\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141443\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141482\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141446\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141462\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141447\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682293\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682294\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141427\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141416\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141430\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141428\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141486\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141481\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141433\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298866\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141423\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141440\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14206265\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13736959\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141435\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141434\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141436\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141419\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141432\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8815\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8815|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/49/15124?source=related_link\">",
"      Bisacodyl: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/56/42883?source=related_link\">",
"      Bisacodyl: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_4_6214="Anterior uveitis II";
var content_f6_4_6214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F85904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F85904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Anterior uveitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The irregular pupil shape is caused by inflammatory adhesion of the iris margin to the anterior lens surface superiorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trobe JD. The Physician's Guide to Eye Care, American Academy of Ophthalmology 1993. Copyright &copy; 1993.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6214=[""].join("\n");
var outline_f6_4_6214=null;
var title_f6_4_6215="Blood supply of the pelvis";
var content_f6_4_6215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Blood supply of the pelvis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 558px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6215=[""].join("\n");
var outline_f6_4_6215=null;
var title_f6_4_6216="Therapeutic angiogenesis for management of refractory angina";
var content_f6_4_6216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapeutic angiogenesis for management of refractory angina",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/4/6216/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/4/6216/contributors\">",
"     Michael Simons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/4/6216/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/4/6216/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/4/6216/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/4/6216/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/4/6216/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in medical therapy and mechanical revascularization have significantly improved outcomes and the quality of life in patients with angina pectoris. In addition, the widespread application of drug-eluting stents has greatly expanded the ability of percutaneous coronary intervention (PCI) to treat patients with complex coronary anatomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these advances, there are patients with angina that is refractory to medical therapy who are not candidates for traditional revascularization (PCI or coronary artery bypass graft surgery [CABG]) because of the inability to achieve complete revascularization or the high risk of CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such patients provide part of the rationale for novel therapeutic strategies to improve both prognosis and the quality of life. Therapeutic angiogenesis is one such option and will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This approach is also being investigated for treatment of patients with peripheral artery disease, including both intermittent claudication and critical limb ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\", section on 'Stimulation of angiogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other investigational strategies, such as transmyocardial laser revascularization and new medications, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28167?source=see_link\">",
"     \"Transmyocardial laser revascularization for management of refractory angina\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39513?source=see_link\">",
"     \"New therapies for angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CONCEPTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapeutic angiogenesis is the induction of new coronary arterial vessels that can effectively provide blood supply to the area of myocardium subtended by a diseased or occluded native coronary arteries. These \"native bypass\" vessels could then relieve myocardial ischemia, improve regional and global left ventricular performance, lessen symptoms of angina, and potentially improve patient prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before discussing the various strategies that have been evaluated for therapeutic angiogenesis, it is important to review the terminology that is used [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/3\">",
"     3",
"    </a>",
"    ]. The term \"angiogenesis\" broadly refers to formation of new vessels. As currently understood, there are three major processes that result in new vessel formation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasculogenesis is a process of blood vessel formation from vascular progenitor cells. This is how the initial circulation forms during embryonic development. Studies in 1990's and early 2000's suggested that there may be circulating endothelial progenitor cells (EPC) that can form vasculature in mature adult tissue. However, more recent studies have demonstrated that EPC are in fact either circulating adult endothelial cells or, most frequently, a subset of monocytes and that no vasculogenesis takes place in adult tissues [",
"      <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/5\">",
"       5",
"      </a>",
"      ]. These cells, however, may promote angiogenesis by the paracrine release of growth factors [",
"      <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      True angiogenesis is de novo capillary growth stimulated by tissue injury, hypoxia, or ischemia.",
"     </li>",
"     <li>",
"      Arteriogenesis is a process of formation of new arteries from either pre-existing collaterals or by de novo arteriogenesis, a process that likely involves arterialization of the capillary bed [",
"      <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The key drivers of angiogenesis are either ischemia, leading to a local activation of vascular endothelial growth factor (VEGF) expression due to activation of hypoxic signaling via a hypoxia-inducible factor (HIF) pathway, or inflammation that leads to local accumulation of VEGF via release from infiltrating inflammatory cells. Thus, the typical processes associated with angiogenesis are wound healing (tissue injury, inflammation) and ischemia (eg ischemic limb). In both of these cases angiogenesis serves a physiologic purpose by either supporting new tissue formation in wound repair or increasing blood supply in the case of ischemia.",
"   </p>",
"   <p>",
"    Pathological angiogenesis occurs in the setting of excess local VEGF production that does not serve a physiologic function. Two prime examples are diabetic retinopathy- excess capillary proliferation in the retina due to inappropriate local release of VEGF, and tumor angiogenesis.",
"   </p>",
"   <p>",
"    In contrast, the biology of arteriogenesis is much less well understood. It is not an ischemia-driven process as collateral arteries form in the areas close to the interruption of a major arterial trunk (eg an occluded common femoral or a proximal coronary artery) and not in the distal bed which is actually ischemic. It seems clear that recruitment of certain circulating mononuclear cells is of critical importance. These cells probably serve as reservoirs of growth factors that promote arterial remodeling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    de novo growth [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However, how they achieve this effect is not understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Restoration of arterial blood supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic considerations strongly suggest that arteriogenesis, not angiogenesis, is the preferred type of neovascularization for restoration of myocardial perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/3,8\">",
"     3,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recruitment of certain circulating mononuclear cells is of critical importance. These cells probably serve as reservoirs of growth factors that promote arterial remodeling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    de novo growth. The incorporation of such cells themselves into the growing vasculature is a low frequency event that is not likely to be of major physiological importance.",
"   </p>",
"   <p>",
"    In a typical patient with atherosclerotic coronary disease, the arterial blood supply to a particular area of the myocardium is compromised because of a high grade stenosis or occlusion of the coronary artery supplying that region. The most effective strategy to restore the arterial blood supply would to provide an alternative bypass around the occlusion. Since atherosclerotic lesions primarily affect epicardial coronary arteries, the required \"bypass\" should be in the same size range to be able to carry bulk flow.",
"   </p>",
"   <p>",
"    It is theoretically possible to restore the blood supply by markedly expanding the capillary bed in the territory served by the compromised coronary artery. However, the degree of expansion required for this purpose is massive and may not be achievable [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/9\">",
"     9",
"    </a>",
"    ]. Despite this limitation, no trial of therapeutic angiogenesis has specifically targeted arteriogenesis as its goal.",
"   </p>",
"   <p>",
"    A number of angiogenic growth factors stimulate blood vessel growth including fibroblast growth factors (FGFs), vascular endothelial growth factors (VEGFs), and platelet-derived growth factor (PDGF). However, none act independently and all have different and poorly understood biologic properties:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VEGFs (in particular VEGF-A) are involved both in capillary growth induced by tissue ischemia and in arteriogenesis. VEGF expression is extremely sensitive to changes in local tissue oxygen levels, a process regulated by hypoxia-inducible factor (HIF)-1-alpha [",
"      <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/10\">",
"       10",
"      </a>",
"      ]. VEGF-A is usually present in limited quantities thereby making regulation of protein levels extremely important for the biological function. Remarkably, even a 50 percent reduction in VEGF expression during development leads to lethality [",
"      <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. In addition to its role in angiogenesis, VEGF also plays a key role in arteriogenesis although how it achieves that is poorly understood.",
"     </li>",
"     <li>",
"      FGFs (FGF1, FGF2, FG4 and FGF5) are abundantly expressed by various cell types. Secretion and cell death leads to accumulation of these long-lived proteins in the extracellular matrix. Further, in contrast to VEGFs, their expression is not sensitive to ischemia or hypoxia. In contrast, the expression of FGF receptors, including both tyrosine kinase receptor FGFR1-R4 and a proteoglycan receptor syndecan-4 is regulated by ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/13\">",
"       13",
"      </a>",
"      ]. FGFs are able to induce both capillary and arterial growth thus participating both in angiogenesis and arteriogenesis. In contrast to VEGFs, FGFs appear to be particularly important in arteriogenesis with growing collaterals demonstrating abundant expression of FGF2 in surrounding monocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHALLENGES IN CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few of the challenges facing researches in developing effective revascularization strategies using biologic agents will be briefly summarized here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The randomization of patients for therapeutic angiogenesis should be based upon age, sex, extent of hypercholesterolemia, and the extent of endogenous collateralization. This will require a sufficiently large numbers of patients (more than 400 per study arm) so that other unknown factors will be evenly distributed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients with unstable angina, such as angina at rest, should be excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=see_link\">",
"     \"Classification of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cancer screening has been carried out in therapeutic angiogenesis trails. There is no compelling evidence that patients should undergo extensive testing for pre-existing malignancies solely because of a decision to start therapeutic angiogenesis. On the other hand, there are disease processes such as proliferative retinopathy that are known to be sensitive to VEGF and proteinuric renal diseases such as membranous nephropathy that may be sensitive to FGFs. Such patients should be excluded in clinical trials evaluating systemic administration of these growth factors.",
"   </p>",
"   <p>",
"    One important question is whether there are populations of patients which are unresponsive to angiogenic therapies, such as patients with diabetes who are resistance to VEGF signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Unfortunately, there are currently no biomarkers available that would aid in selecting the correct population and in evaluating the therapeutic response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Delivery of growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;How to effectively and safely deliver growth factors remains a major problem in therapeutic angiogenesis trials. Simple systemic (intravenous) infusions have either not been effective when used short-term or have not been tried long-term because of the fear of side effects. Methods of local delivery to the heart have included simple intracoronary infusion, which has been ineffective for both proteins and viruses, intramyocardial injections, pericardial administration, and locally applied polymer-based delivery.",
"   </p>",
"   <p>",
"    It is not clear that any of these approaches is better than the others or that any are effective. Active research in this area includes retrograde coronary sinus delivery and the development of effective delivery devices and of noninvasive guidance techniques, such as electromechanical mapping that can distinguish between healthy and infarcted myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/19\">",
"     19",
"    </a>",
"    ] and live three-dimensional echocardiography that accurately locates the tip of the delivery catheter in space [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Protein versus gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emerging consensus is that effective angiogenic intervention will require the prolonged presence (perhaps four to six weeks) of the therapeutic agent at the desired site of action. This cannot be achieved with single dose injections due to the short half-life of proteins in tissues. Repeat administration or the use of a sustained release polymer may prove effective.",
"   </p>",
"   <p>",
"    Both plasmid and adenoviral based gene therapy approaches suffer from relatively short expression times (one to three days for plasmid, seven to fourteen days for adenovirus) and, with plasmid, relatively low expression levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Trial endpoints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the majority of patients currently being enrolled in therapeutic angiogenesis trials are selected on the basis of symptoms of angina and not life-threatening ischemia, quality of life measures should be the primary end point. Use of quality-of-life instruments such as the Short Form (SF) 36 (",
"    <a class=\"external\" href=\"file://www.sf-36.com/\">",
"     file://www.sf-36.com",
"    </a>",
"    ) and the Seattle Angina Questionnaire may be appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ideally, an angiogenesis-specific, quality-of-life assessment tool should be developed. Such instruments, which should be self-administered, must be reliable, validated, and scored by standard algorithms. Since there is a strong placebo effect with regard to quality-of-life, the patient, the referring physician, and the investigator must be blinded to the specific treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of skepticism regarding subjective symptom assessment, much emphasis has been placed upon demonstration of physiologic improvements in myocardial perfusion and function. The goal is logical but has been technically challenging.",
"   </p>",
"   <p>",
"    Exercise testing may or may not be a useful trial end point. Patients with variable baseline test results (&gt;30 percent difference) as well as those with only minimally impaired exercise tolerance should be excluded from clinical trials. Pharmacological stress testing may be preferred to exercise protocols. Semiquantitative or quantitative SPECT analysis is the most accepted tool at present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pro-angiogenic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The field has been dominated by the use of various vascular growth factors including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and hepatocyte growth factor (HGF). As already discussed, a number of patients appear to demonstrate resistance to VEGF and perhaps other growth factors. Animal trials show that unlike responses in young, healthy animals, VEGF (and other factors) are much less effective in older atherosclerotic or diabetic animals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/22\">",
"     22",
"    </a>",
"    ]. If the VEGF-activated arteriogenic pathway was clearly understood, agents could be developed to activate it bypassing VEGF receptor signaling resistance in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     VEGF",
"    </span>",
"   </p>",
"   <p>",
"    There are five members of the vascular endothelial growth factor (VEGF) family, with VEGF-A being the most extensively studied. VEGF therapy has been evaluated in studies administering the VEGF protein and in gene therapy trials in which the gene for VEGF was administered in a plasmid or viral vector.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     VIVA trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the initial open label phase I of VEGF-A intracoronary infusion in patients with coronary heart disease (CHD) was interpreted as positive, this was not confirmed in VIVA, a randomized, double-blind, placebo-controlled phase II trial of intracoronary recombinant human VEGF (VIVA) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/23\">",
"     23",
"    </a>",
"    ]. In this trial, 178 patients were assigned to placebo or to VEGF given at a either low or high doses. The infusion were given into coronary arteries for 10 minutes, followed by three repeat intravenous infusions over the following nine days. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 60 days, there were no significant differences in exercise tolerance or angina class between the treated and control groups.",
"     </li>",
"     <li>",
"      At 120 days, patients receiving high dose VEGF had a significant improvement in angina class in compared to the other two groups. However, nuclear perfusion imaging showed no differences among the three groups, raising doubt about the improvement in angina. This suggests that angina class may not be a good end-point for trials of this intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     KAT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The KAT trial randomly assigned 103 patients with symptomatic myocardial ischemia to VEGF DNA in a plasmid liposome, an adenoviral vector, or control via intracoronary infusion at the time of percutaneous coronary intervention (90 percent with stents) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/24\">",
"     24",
"    </a>",
"    ]. At six months, a significant improvement in myocardial perfusion using stress technetium-99m sestamibi SPECT imaging was seen in patients receiving adenoviral VEGF, but not those treated with plasmid VEGF or controls. There were no significant improvements in exercise time, functional class, or restenosis rate. However, the use of PCI and the small numbers of patients makes it difficult to interpret these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Euroinject One trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Euroinject One trial randomly assigned 80 patients with advanced coronary heart disease but not further medical or revascularization options to receive either phVEGF-A (165) or placebo plasmid in the myocardial region showing stress-induced myocardial perfusion defects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/25\">",
"     25",
"    </a>",
"    ]. At three months, there were no significant differences between the groups on analysis of myocardial stress perfusion defects or on semiquantitative analysis of the change in perfusion in the treated region. However, NOGA mapping showed some improvement in regional ventricular function in the treated group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     NORTHERN Trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trial enrolled 93 patients with refractory class 3 or 4 angina and randomly assigned them to injection VEGF-A plasmid or placebo. There was no difference in VEGF-treated or placebo treated patients after 3 or 6 months with regard to SPECT-assessed ischemic burden. Interestingly, both groups demonstrated a significant reduction in the ischemic burden over time.",
"   </p>",
"   <p>",
"    Other members of VEGF family such as VEGF-B and PlGF have been tested in pre-clinical setting but to date there are no clinical studies of their efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     FIBROBLAST GROWTH FACTORS",
"    </span>",
"   </p>",
"   <p>",
"    There are 22 members of the FGF growth factor family. FGF1, FGF2 and FGF-4 have received the most extensive evaluation to date.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     FGF-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;FGF-2 (basic FGF or bFGF) has been evaluated in several clinical trials. The largest trial, the FGF Initiating Revascularization Support Trial (FIRST) trial, randomly assigned 337 patients who were ineligible for angioplasty or revascularization to placebo or one of three doses of intracoronary recombinant FGF-2 (0.3, 3, or 30",
"    <span class=\"nowrap\">",
"     &micro;g/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/26\">",
"     26",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 90 days, there was no significant improvement in exercise treadmill time or nuclear perfusion parameters among the treatment groups. However, there was an improvement in patient and physician perception of angina as assessed by the Seattle Angina Questionnaire and the Canadian Cardiovascular Society angina classification (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      At 180 days, there were no significant differences between the treatment groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A smaller trial of 24 patients evaluated the efficacy of local application of an FGF-2 containing polymer at the time of bypass surgery to the area of myocardium that could not be revascularized during the procedure. Patients receiving high-dose of FGF-2 (100 mg) had a significant improvement in perfusion of the target area compared to low-dose FGF-2 (10 mg) or placebo controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/27\">",
"     27",
"    </a>",
"    ]. Three years later, the patients receiving high-dose FGF-2 had significantly less angina than placebo controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/28\">",
"     28",
"    </a>",
"    ]. Although encouraging, interpretation of these results is clouded by the presence of concomitant bypass surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FGF-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and efficacy of intramyocardial FGF-1 (acidic FGF or aFGF) was evaluated in 20 patients with three vessel disease undergoing CABG; FGF-1 was injected at the site of the left internal mammary artery to left anterior descending artery anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/29\">",
"     29",
"    </a>",
"    ]. Coronary angiography performed two weeks after FGF-1 injection showed a capillary blush at the site of injection in a majority of patients. No significant side effects were noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     FGF-4",
"    </span>",
"    &nbsp;&mdash;&nbsp;A series of AGENT trials examined the safety and efficacy of intracoronary injections of an adenoviral-encoded FGF-4 gene. The AGENT-1 trial enrolled 79 patients who were randomly assigned to various doses of Ad-FGF4 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients in two dose groups had a trend toward a greater increase in exercise time at four weeks compared to the placebo group (1.3 versus 0.7 minutes), while patients with a baseline exercise time &le;10 minutes had a significant increase in exercise time (1.6 versus 0.6 minutes).",
"   </p>",
"   <p>",
"    The subsequent AGENT-2 trial of FGF-4 gene transfer evaluated 52 patients with stable angina and reversible ischemia on adenosine technetium-99m sestamibi SPECT imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients received gene therapy had a nonsignificant reduction in the size of the ischemic defect compared to no change among those receiving placebo.",
"   </p>",
"   <p>",
"    Two large double-blind phase III trials of Ad-FGF4 (AGENT-3 and AGENT-4) were negative for their primary end point although an over-optimistic analysis suggested a benefit in a certain population of middle aged women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/32\">",
"     32",
"    </a>",
"    ]. There are, however, no biological reasons to support this conjecture.",
"   </p>",
"   <p>",
"    A particular issue that probably doomed the Ad-FGF4 strategy was its intracoronary administration. Animal studies show very little myocardial uptake of an intracoronary infused adenovirus in intact arterial beds [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/33\">",
"     33",
"    </a>",
"    ]. Thus, this strategy was doomed to failure because of inefficient delivery. On the other hand, the AGENT program is a clear demonstration of the safety of short-term adenoviral therapy in a large cohort of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     GM-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine secreted by a wide variety of cell types that acts broadly upon hematopoietic cells. Activated macrophages can induce vascular proliferation, suggesting a role for the administration of recombinant human GM-CSF (rhGM-CSF). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=see_link\">",
"     \"Introduction to recombinant hematopoietic growth factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible efficacy was examined in an initial trial of 21 patients with severe inoperable coronary disease who were randomly assigned to placebo or intracoronary rhGM-CSF followed by two weeks of subcutaneous drug [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/34\">",
"     34",
"    </a>",
"    ]. Compared to placebo, rhGM-CSF improved collateral flow, measured by intracoronary sensor guidewires, and reduced ECG signs of ischemia during coronary balloon inflation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     HEPARIN AND ADENOSINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animals,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    can accelerate the formation of coronary collaterals induced by ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/35\">",
"     35",
"    </a>",
"    ]. Clinical studies have shown that the use of heparin to treat repeated episodes of exercise-induced ischemia can improve myocardial perfusion and reduced ECG evidence of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various models of ischemic preconditioning, which refers to the protection conferred to ischemic myocardium by preceding brief periods of sublethal ischemia, have implicated the involvement of adenosine, which is released locally during ischemia and may have a protective role. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9673?source=see_link\">",
"     \"Definition and pathogenesis of ischemic preconditioning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and adenosine as treatment for refractory angina was evaluated in a study of 21 patients with chronic stable angina that was refractory to conventional medical therapy; the patients were not candidates for revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/37\">",
"     37",
"    </a>",
"    ]. Heparin (10,000 U) and adenosine (140",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min for six minutes) were administered daily for 10 days. Compared to placebo, heparin and adenosine reduced the extent (by 9 percent) and severity (by 14 percent) of myocardial perfusion abnormalities on imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     POTENTIAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of potential complications associated with therapeutic angiogenesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aberrant vascular proliferation in adjacent and perhaps distant nontargeted tissues.",
"     </li>",
"     <li>",
"      Increased vascular permeability; the ensuing extravasation of plasma and plasma proteins into tissues can trigger the clotting system, leading to the deposition of fibrin gel and the development of edema, induction of new blood vessels, and fibroblast activation.",
"     </li>",
"     <li>",
"      Triggering of growth of coexisting, but unrecognized, neoplasms or the development of de novo tumors.",
"     </li>",
"     <li>",
"      Proatherogenic effects, including an increase in neointimal smooth muscle cell proliferation, neointimal mass, and vaso vasorum supplying the atherosclerotic lesions. As an example, VEGF promotes monocyte activation and migration and can induce a local inflammatory reaction, changes that could promote atherosclerosis and plaque development. Consistent with this hypothesis are the observations in atherosclerosis-prone animals that human recombinant VEGF increased the rate and degree of atherosclerotic plaque formation in the thoracic aorta and that inhibitors of angiogenesis reduced intimal neovascularization and plaque growth [",
"      <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hazards associated with viral vectors, as the transfection of cells with replication-incompetent adenoviral vectors may induce immune or inflammatory responses.",
"     </li>",
"     <li>",
"      Hazards associated with direct myocardial delivery of angiogenic factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these potential complications, few significant complications have been observed in angiogenesis trials to date.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are patients with angina that is refractory to medical therapy who are not candidates for traditional revascularization (PCI or coronary artery bypass graft surgery [CABG]) because of the inability to achieve complete revascularization or the high risk of CABG. Therapeutic angiogenesis is under investigation as one option for improving the quality of life in these patients.",
"   </p>",
"   <p>",
"    The goal of therapeutic angiogenesis is the induction of new coronary arterial vessels that can effectively provide blood supply to the area of myocardium subtended by a diseased or occluded native coronary arteries. A number of angiogenic growth factors stimulate blood vessel growth including fibroblast growth factors (FGFs), vascular endothelial growth factors (VEGFs), and platelet-derived growth factor (PDGF) and many of these are under investigation. To date none of them has been shown to have clinical utility.",
"   </p>",
"   <p>",
"    The difficulty in translating experimental successes with pro-angiogenic therapy to clinical practice probably stems from three key sources &mdash; ineffective delivery (especially in myocardial angiogenesis trials), the presence of co-morbid conditions (diabetes, atherosclerosis, etc.) that can inhibit angiogenic signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/18\">",
"     18",
"    </a>",
"    ], and advanced age of patients in trials [",
"    <a class=\"abstract\" href=\"UTD.htm?6/4/6216/abstract/39\">",
"     39",
"    </a>",
"    ]. Finally, it is also quite likely that choosing the \"no-option\" population for these trials results in selection of patients with genetic defects preventing new vessel formation.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/1\">",
"      Mukherjee D, Comella K, Bhatt DL, et al. Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization. Am Heart J 2001; 142:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/2\">",
"      Khurana R, Simons M, Martin JF, Zachary IC. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005; 112:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/3\">",
"      Simons M. Angiogenesis: where do we stand now? Circulation 2005; 111:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/4\">",
"      Simons M, Ware JA. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov 2003; 2:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/5\">",
"      Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007; 109:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/6\">",
"      Pearson JD. Endothelial progenitor cells - hype or hope? J Thromb Haemost 2009; 7:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/7\">",
"      Schaper W, Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003; 23:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/8\">",
"      Heil M, Eitenm&uuml;ller I, Schmitz-Rixen T, Schaper W. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med 2006; 10:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/9\">",
"      Helisch A, Schaper W. Arteriogenesis: the development and growth of collateral arteries. Microcirculation 2003; 10:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/10\">",
"      Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/11\">",
"      Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/12\">",
"      Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/13\">",
"      Simons M. Integrative signaling in angiogenesis. Mol Cell Biochem 2004; 264:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/14\">",
"      Arras M, Ito WD, Scholz D, et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 1998; 101:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/15\">",
"      Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation 2000; 102:E73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/16\">",
"      Tchaikovski V, Olieslagers S, B&ouml;hmer FD, Waltenberger J. Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes. Circulation 2009; 120:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/17\">",
"      Simons M. Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed? J Am Coll Cardiol 2005; 46:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/18\">",
"      Simons M. Diabetic monocyte and vascular endothelial growth factor signaling impairment. Circulation 2009; 120:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/19\">",
"      Keck A, Hertting K, Schwartz Y, et al. Electromechanical mapping for determination of myocardial contractility and viability. A comparison with echocardiography, myocardial single-photon emission computed tomography, and positron emission tomography. J Am Coll Cardiol 2002; 40:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/20\">",
"      Baklanov DV, de Muinck ED, Simons M, et al. Live 3D echo guidance of catheter-based endomyocardial injection. Catheter Cardiovasc Interv 2005; 65:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/21\">",
"      Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 1995; 25:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/22\">",
"      Tirziu D, Moodie KL, Zhuang ZW, et al. Delayed arteriogenesis in hypercholesterolemic mice. Circulation 2005; 112:2501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/23\">",
"      Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003; 107:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/24\">",
"      Hedman M, Hartikainen J, Syv&auml;nne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/25\">",
"      Kastrup J, J&oslash;rgensen E, R&uuml;ck A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005; 45:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/26\">",
"      Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002; 105:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/27\">",
"      Laham RJ, Sellke FW, Edelman ER, et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999; 100:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/28\">",
"      Ruel M, Laham RJ, Parker JA, et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002; 124:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/29\">",
"      Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/30\">",
"      Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/31\">",
"      Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003; 42:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/32\">",
"      Henry TD, Grines CL, Watkins MW, et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 2007; 50:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/33\">",
"      Wright MJ, Wightman LM, Latchman DS, Marber MS. In vivo myocardial gene transfer: optimization and evaluation of intracoronary gene delivery in vivo. Gene Ther 2001; 8:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/34\">",
"      Seiler C, Pohl T, Wustmann K, et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001; 104:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/35\">",
"      Unger EF, Sheffield CD, Epstein SE. Heparin promotes the formation of extracardiac to coronary anastomoses in a canine model. Am J Physiol 1991; 260:H1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/36\">",
"      Melandri G, Semprini F, Cervi V, et al. Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial. Circulation 1993; 88:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/37\">",
"      Barron HV, Sciammarella MG, Lenihan K, et al. Effects of the repeated administration of adenosine and heparin on myocardial perfusion in patients with chronic stable angina pectoris. Am J Cardiol 2000; 85:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/38\">",
"      Drinane M, Mollmark J, Zagorchev L, et al. The antiangiogenic activity of rPAI-1(23) inhibits vasa vasorum and growth of atherosclerotic plaque. Circ Res 2009; 104:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/4/6216/abstract/39\">",
"      Tirziu D, Simons M. Angiogenesis in the human heart: gene and cell therapy. Angiogenesis 2005; 8:241.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1537 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-1D88657B2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6216=[""].join("\n");
var outline_f6_4_6216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CONCEPTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Terminology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Restoration of arterial blood supply",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHALLENGES IN CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Delivery of growth factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Protein versus gene therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Trial endpoints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pro-angiogenic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      VEGF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      VIVA trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      KAT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Euroinject One trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NORTHERN Trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      FIBROBLAST GROWTH FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      FGF-2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FGF-1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      FGF-4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      GM-CSF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      HEPARIN AND ADENOSINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      POTENTIAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1537\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1537|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=related_link\">",
"      Classification of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9673?source=related_link\">",
"      Definition and pathogenesis of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=related_link\">",
"      Introduction to recombinant hematopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39513?source=related_link\">",
"      New therapies for angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28167?source=related_link\">",
"      Transmyocardial laser revascularization for management of refractory angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=related_link\">",
"      Treatment of chronic lower extremity critical limb ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_4_6217="12 lead ECG orthodromic AVRT";
var content_f6_4_6217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1217px;\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) showing orthodromic atrioventricular reentrant tachycardia (AVRT) in a patient with an accessory AV pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG from a patient with Wolff-Parkinson-White shows a regular tachycardia. However, in contrast to the QRS pattern during sinus rhythm, the QRS complexes are narrow, without evidence of a delta wave or preexcitation; this is due to the fact that antegrade ventricular activation occurs via the normal atrioventricular node-His Purkinje pathway while retrograde atrial activation is via the accessory pathway. Therefore, this is called an orthodromic atrioventricular reentrant tachycardia or OAVRT.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    ECG in Wolff-Parkinson-White",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG shows the typical features of Wolff-Parkinson-White; the PR interval is short (*) and the QRS duration prolonged as a result of a delta wave (arrow), indicating ventricular preexcitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6217=[""].join("\n");
var outline_f6_4_6217=null;
var title_f6_4_6218="Everolimus: Drug information";
var content_f6_4_6218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Everolimus: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/11/38070?source=see_link\">",
"    see \"Everolimus: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/41/20121?source=see_link\">",
"    see \"Everolimus: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10223925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7418605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Afinitor&reg;;",
"     </li>",
"     <li>",
"      Afinitor&reg; Disperz;",
"     </li>",
"     <li>",
"      Zortress&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13209898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Afinitor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7674090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, mTOR Kinase Inhibitor;",
"     </li>",
"     <li>",
"      Immunosuppressant Agent;",
"     </li>",
"     <li>",
"      mTOR Kinase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7674213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Tablets (Afinitor&reg;, Zortress&reg;) and tablets for oral suspension (Afinitor&reg; Disperz) are not interchangeable; Afinitor&reg; Disperz is only indicated for the treatment of subependymal giant cell astrocytoma (SEGA), in conjunction with therapeutic monitoring. Do not combine formulations to achieve desired dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Breast cancer, advanced, hormone receptor-positive, HER2-negative:",
"     </b>",
"     Oral: 10 mg once daily (in combination with exemestane), continue treatment until no longer clinically beneficial or until unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pancreatic neuroendocrine tumors (PNET), advanced:",
"     </b>",
"     Oral: 10 mg once daily, continue treatment until no longer clinically beneficial or until unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Renal angiomyolipoma:",
"     </b>",
"     Oral: 10 mg once daily, continue treatment until no longer clinically beneficial or until unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Renal cell cancer, advanced (RCC):",
"     </b>",
"     Oral: 10 mg once daily, continue treatment until no longer clinically beneficial or until unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Liver transplantation, rejection prophylaxis (begin at least 30 days post-transplant):",
"     </b>",
"     Oral: Initial: 1 mg twice daily; adjust maintenance dose if needed at a 4- to 5-day interval (from prior dose adjustment) based on serum concentrations, tolerability, and response; goal serum concentration is between 3 and 8 ng/mL (based on an LC/MS/MS assay method); administer in combination with tacrolimus (reduced dose required) and corticosteroids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Renal transplantation, rejection prophylaxis:",
"     </b>",
"     Oral: Initial: 0.75 mg twice daily; adjust maintenance dose if needed at a 4- to 5-day interval (from prior dose adjustment) based on serum concentrations, tolerability, and response; goal serum concentration is between 3 and 8 ng/mL (based on an LC/MS/MS assay method); administer in combination with basiliximab induction and concurrently with cyclosporine (dose adjustment required) and corticosteroids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Subependymal giant cell astrocytoma (SEGA; dosing based on body surface area [BSA]):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     U.S. labeling: Initial dose: 4.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily; round to nearest tablet (tablet or tablet for oral suspension) size.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Canadian labeling: Initial dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     0.5-1.2 m",
"     <sup>",
"      2",
"     </sup>",
"     : 2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1.3-2.1 m",
"     <sup>",
"      2",
"     </sup>",
"     : 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;2.2 m",
"     <sup>",
"      2",
"     </sup>",
"     : 7.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Assess whole blood trough concentrations ~2 weeks after everolimus initiation or with dosage modifications, initiation or changes to concurrent CYP3A4 inhibitor/inducer therapy, or changes in hepatic impairment;  adjust maintenance dose if needed at 2-week intervals to achieve and maintain trough concentrations between 5 and 15 ng/mL; monitor trough concentrations routinely; once stable dose is attained and if BSA is stable throughout treatment, monitor trough concentrations every 6-12 months; monitor every 3-6 months if BSA is changing. Continue until disease progression or unacceptable toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     If trough &lt;5 ng/mL: Increase dose by 2.5 mg/day (tablets) or 2 mg/day (tablets for oral suspension)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     If trough &gt;15 ng/mL: Reduce dose by 2.5 mg/day (tablets) or 2 mg/day (tablets for oral suspension)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     If dose reduction necessary in patients receiving the lowest strength available, administer every other day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Carcinoid tumors, advanced (unlabeled use):",
"     </b>",
"     Oral: 10 mg once daily (in combination with octreotide LAR) until disease progression or toxicity (Pavel, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Waldenstr&ouml;m's macroglobulinemia, relapsed or refractory (unlabeled use):",
"     </b>",
"     Oral: 10 mg once daily until disease progression or toxicity (Ghobrial, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment for concomitant CYP3A4 inhibitors/inducers and/or P-gp inhibitors:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Breast cancer, PNET, RCC, renal angiomyolipoma:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CYP3A4 inducers:",
"     </i>",
"     Strong inducers: Avoid concomitant administration with strong CYP3A4 inducers; if concomitant use cannot be avoided, consider adjusting everolimus dose upward in 5 mg increments up to 20 mg daily, with careful monitoring. If the strong CYP3A4 enzyme inducer is discontinued, reduce the everolimus to the recommended starting dose or to the dose used prior to initiation of the CYP3A4 inducer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CYP3A4 or P-gp inhibitors:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Strong inhibitors: Avoid concomitant administration with strong CYP3A4 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Moderate CYP3A4 and/or P-gp inhibitors:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     U.S. labeling: Reduce everolimus dose to 2.5 mg once daily; may consider increasing from 2.5 mg to 5 mg once daily based on patient tolerance. When the moderate inhibitor is discontinued, allow ~2-3 days to elapse prior to adjusting the everolimus upward to the recommended starting dose or to the dose used prior to initiation of the moderate inhibitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Canadian labeling: Reduce everolimus dose by 50%; further reductions may be necessary for adverse reactions. If dose reduction is required for patients receiving the lowest available strength, consider alternate day dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Renal transplantation:",
"      </i>",
"     </b>",
"     Dosage adjustments may be necessary based on everolimus serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       SEGA:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CYP3A4 inducers:",
"     </i>",
"     Strong inducers:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     U.S. labeling: Avoid concomitant administration with strong CYP3A4 inducers; if concomitant use cannot be avoided, an initial starting everolimus dose of 9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily is recommended, or, double the everolimus dose; individualize subsequent dose adjustments based on therapeutic drug monitoring. If the strong CYP3A4 enzyme inducer is discontinued, reduce the everolimus dose by ~50% or to the dose used prior to initiation of the CYP3A4 inducer; reassess trough concentration after ~2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Canadian labeling: Avoid concomitant administration with strong CYP3A4 inducers; if concomitant use cannot be avoided and everolimus level &lt;5 ng/mL, may increase daily dose by 2.5 mg every two weeks until target everolimus trough concentration is 5-10 ng/mL. Evaluate trough concentration and tolerability prior to each dosage adjustment.  If the strong CYP3A4 enzyme inducer is discontinued, reduce everolimus to the dose used prior to initiation of the CYP3A4 inducer; reassess trough concentration after ~2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CYP3A4 or P-gp inhibitors:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Strong inhibitors: Avoid concomitant administration with strong CYP3A4 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Moderate CYP3A4 and/or P-gp inhibitors: Initial everolimus dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     U.S. labeling: 2.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily or reduce everolimus dose by ~50% (if dose reduction is required for patients receiving the lowest strength available, consider alternate day dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Canadian labeling: Reduce everolimus dose by ~50% (if dose reduction is required for patients receiving the lowest strength available, consider alternate day dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Assess trough concentrations after ~2 weeks; individualize dosing based on therapeutic drug monitoring. If the moderate inhibitor is discontinued, allow 2-3 days to elapse prior to adjusting the everolimus upward by ~50% or to the dose used prior to initiation of the moderate inhibitor; reassess trough concentrations after ~2 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10953367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/41/20121?source=see_link\">",
"      see \"Everolimus: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Tablets (Afinitor&reg;, Zortress&reg;) and tablets for oral suspension (Afinitor&reg; Disperz) are not interchangeable. Do not combine formulations to achieve desired dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Subependymal giant cell astrocytoma (SEGA):",
"     </b>",
"     Children &ge;1 year (U.S. labeling) or &ge;3 years (Canadian labeling): Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7674214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7674215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7674216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Mild impairment (Child-Pugh class A):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Breast cancer, PNET, RCC, renal angiomyolipoma:",
"     </i>",
"     Reduce dose to 7.5 mg once daily; if not tolerated, may further reduce to 5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Liver or renal transplantation:",
"     </i>",
"     Reduce initial dose by ~33%; individualize subsequent dosing based on therapeutic drug monitoring (target trough concentration: 3-8 ng/mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      SEGA:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     U.S. labeling: Adjustment to initial dose may not be necessary; subsequent dosing is based on therapeutic drug monitoring (monitor ~2 weeks after initiation, dosage modifications, or after any change in hepatic status; target trough concentration: 5-15 ng/mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Canadian labeling: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     0.5-1.2 m",
"     <sup>",
"      2",
"     </sup>",
"     : 2.5 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1.3-2.1 m",
"     <sup>",
"      2",
"     </sup>",
"     : 2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;2.2 m",
"     <sup>",
"      2",
"     </sup>",
"     : 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;\">",
"     <b>",
"      Moderate impairment (Child-Pugh class B):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Breast cancer, PNET, RCC, renal angiomyolipoma:",
"     </i>",
"     Reduce dose to 5 mg once daily; if not tolerated, may further reduce to 2.5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Liver or renal transplantation:",
"     </i>",
"     Reduce initial dose by ~50%; individualize subsequent dosing based on therapeutic drug monitoring (target trough concentration: 3-8 ng/mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      SEGA:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     U.S. labeling: Adjustment to initial dose may not be necessary; subsequent dosing is based on therapeutic drug monitoring (monitor ~2 weeks after initiation, dosage modifications, or after any change in hepatic status; target trough concentration: 5-15 ng/mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Canadian labeling: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     0.5-1.2 m",
"     <sup>",
"      2",
"     </sup>",
"     : 2.5 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;1.3 m",
"     <sup>",
"      2",
"     </sup>",
"     : 2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Severe impairment (Child-Pugh class C):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Breast cancer, PNET, RCC, renal angiomyolipoma:",
"     </i>",
"     If potential benefit outweighs risks, a maximum dose of 2.5 mg once daily may be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Liver or renal transplantation:",
"     </i>",
"     Reduce initial dose by ~50%; individualize subsequent dosing based on therapeutic drug monitoring (target trough concentration: 3-8 ng/mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      SEGA:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     U.S. labeling: Reduce initial dose to 2.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily (or current dose by ~50%); subsequent dosing is based on therapeutic drug monitoring",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Canadian labeling: Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F7674217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      <i>",
"       Breast cancer (adjustments apply to everolimus), PNET, RCC, renal angiomyolipoma, SEGA: Reduce everolimus dose by ~50% if dosage adjustment is necessary:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Noninfectious pneumonitis:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 1 (asymptomatic radiological changes suggestive of pneumonitis): No dosage adjustment necessary; monitor appropriately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 2 (symptomatic but not interfering with activities of daily living [ADL]): Consider interrupting treatment, rule out infection, and consider corticosteroids until symptoms improve to &le;grade 1; reinitiate at a lower dose. (Discontinue if recovery does not occur within 4 weeks.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 3 (symptomatic, interferes with ADL; oxygen indicated): Interrupt treatment until symptoms improve to &le;grade 1; rule out infection and consider corticosteroid treatment; may reinitiate at a lower dose. If grade 3 toxicity recurs, consider discontinuing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 4 (life-threatening; ventilatory support indicated): Discontinue treatment; rule out infection; consider corticosteroid treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Stomatitis (avoid the use of products containing alcohol, hydrogen peroxide, iodine, or thyme derivatives):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 1 (minimal symptoms, normal diet): No dosage adjustment necessary; manage with mouth wash (nonalcoholic or isotonic salt water) several times a day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 2 (symptomatic but can eat and swallow modified diet): Interrupt treatment until symptoms improve to &le;grade 1; reinitiate at same dose; if stomatitis recurs at grade 2, interrupt treatment until symptoms improve to &le;grade 1 and then reinitiate at a lower dose. Also manage with topical (oral) analgesics (eg, benzocaine, butyl aminobenzoate, tetracaine, menthol, or phenol) &plusmn; topical (oral) corticosteroids (eg, triamcinolone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 3 (symptomatic and unable to orally aliment or hydrate adequately): Interrupt treatment until symptoms improve to &le;grade 1; then reinitiate at a lower dose. Also manage with topical (oral) analgesics (eg, benzocaine, butyl aminobenzoate, tetracaine, menthol, or phenol) &plusmn; topical (oral) corticosteroids (eg, triamcinolone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 4 (life-threatening symptoms): Discontinue treatment; initiate appropriate medical intervention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Metabolic toxicity (eg, hyperglycemia, dyslipidemia):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 1: No dosage adjustment necessary; initiate appropriate medical intervention and monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 2: No dosage adjustment necessary; manage with appropriate medical intervention and monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 3: Temporarily interrupt treatment; reinitiate at a lower dose; manage with appropriate medical intervention and monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 4: Discontinue treatment; manage with appropriate medical intervention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Nonhematologic toxicities (excluding pneumonitis, stomatitis, or metabolic toxicity):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 1: If toxicity is tolerable, no dosage adjustment necessary; initiate appropriate medical intervention and monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 2: If toxicity is tolerable, no dosage adjustment necessary; initiate appropriate medical intervention and monitor. If toxicity becomes intolerable, temporarily interrupt treatment until improvement to &le;grade 1 and reinitiate at the same dose; if toxicity recurs at grade 2, temporarily interrupt treatment until improvement to &le; grade 1 and then reinitiate at a lower dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 3: Temporarily interrupt treatment until improvement to &le;grade 1; initiate appropriate medical intervention and monitor. May reinitiate at a lower dose; if toxicity recurs at grade 3, consider discontinuing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Grade 4 (life-threatening symptoms): Discontinue treatment; initiate appropriate medical intervention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      <i>",
"       Liver or renal transplantation:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Evidence of polyoma virus infection or PML: Consider reduced immunosuppression (taking into account the allograft risks associated with decreased immunosuppression)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Pneumonitis (grade 4 symptoms) or invasive systemic fungal infection: Discontinue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      <i>",
"       SEGA:",
"      </i>",
"     </b>",
"     <i>",
"      Other severe/intolerable adverse reactions:",
"     </i>",
"     Temporarily reduce dose (by ~50% from prior dose) and/or temporarily interrupt treatment; if dose reduction is required for patients receiving the lowest available strength, consider alternate day dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7674251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Afinitor&reg;: 2.5 mg, 5 mg, 7.5 mg, 10 mg [contains lactose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zortress&reg;: 0.25 mg, 0.5 mg, 0.75 mg [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7674088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F14949342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Afinitor Disperz (tablets for oral suspension): FDA approved August 2012; anticipated availability in November 2012. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10223926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Zortress&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM209840.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM209840.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7674201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     May be taken with or without food; to reduce variability, take consistently with regard to food. Afinitor&reg; missed doses may be taken up to 6 hours after regularly scheduled time; if &gt; 6 hours, resume at next regularly scheduled time.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Swallow whole with a glass of water. Do not break, chew, or crush (do not administer tablets that are crushed or broken).  Avoid contact with or exposure to crushed or broken tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets for oral suspension: Administer as a suspension only. Administer immediately after preparation; discard if not administered within 60 minutes after preparation. Prepare suspension in water only. Do not break or crush tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Preparation in an oral syringe:",
"     </i>",
"     Place dose into 10 mL oral syringe (maximum 10 mg/syringe; use an additional syringe for doses &gt;10 mg). Draw ~5 mL of water and ~4 mL of air into oral syringe; allow to sit (tip up) in a container until tablets are in suspension (3 minutes). Gently invert syringe 5 times immediately prior to administration; administer contents, then add ~5 mL water and ~4 mL of air to same syringe, swirl to suspend remaining particles and administer entire contents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Preparation in a small glass:",
"     </i>",
"     Place dose into a small glass (&le;100 mL) containing ~25 mL water (maximum 10 mg/glass; use and additional glass for doses &gt;10 mg); allow to sit until tablets are in suspension (3 minutes). Stir gently with spoon immediately prior to administration; administer contents, then add ~25 mL water to same glass, swirl with same spoon to suspend remaining particles and administer entire contents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Breast cancer, pancreatic neuroendocrine tumors, renal cell cancer, renal angiolipoma, SEGA: Administer at the same time each day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liver transplantation: Administer consistently ~12 hours apart; administer at the same time as tacrolimus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal transplantation: Administer consistently ~12 hours apart; administer at the same time as cyclosporine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7674091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Afinitor&reg;: Treatment of advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (in combination with exemestane and after letrozole or anastrozole failure); treatment of advanced renal cell cancer (RCC), after sunitinib or sorafenib failure; treatment of renal angiomyolipoma with tuberous sclerosis complex  (TSC) not requiring immediate surgery; treatment of subependymal giant cell astrocytoma (SEGA) associated with TSC which requires intervention, but cannot be curatively resected; treatment of advanced, metastatic or unresectable pancreatic neuroendocrine tumors (PNET)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Afinitor&reg; Disperz: Treatment of subependymal giant cell astrocytoma (SEGA) associated with TSC which requires intervention, but cannot be curatively resected",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zortress&reg;: Prophylaxis of organ rejection in renal transplantation patients at low-moderate immunologic risk (in combination with basiliximab, cyclosporine, and corticosteroids); prophylaxis of organ rejection in liver transplantation (in combination with tacrolimus and corticosteroids)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7674092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsed or refractory Waldenstr&ouml;m's macroglobulinemia (WM); treatment of progressive advanced carcinoid tumors",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7674085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Everolimus may be confused with sirolimus, tacrolimus, temsirolimus",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tablets (Afinitor&reg;, Zortress&reg;) and tablets for oral suspension (Afinitor&reg; Disperz) are not interchangeable; do not combine formulations to achieve desired dose.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7674166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (4% to 45%), hypertension (4% to 30%; hypertensive crisis: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (7% to 45%), fever (15% to 32%), headache (18% to 30%), seizure (5% to 29%), anxiety/aggression/behavioral disturbance (SEGA: 21%), insomnia (6% to 17%), dizziness (7% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (18% to 59%), acneiform dermatitis (3% to 25%), nail disorders (5% to 22%), acne (3% to 22%), cellulitis (SEGA: 29%), pruritus (13% to 21%), dry skin (9% to 18%), contact dermatitis (14%), excoriation (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (17% to 85%), hyperglycemia (12% to 75%; grades 3/4: &lt;1% to 17%), hypertriglyceridemia (&le;73%), bicarbonate decreased (&le;56%), hypophosphatemia (9% to 49%), hypocalcemia (17% to 37%), albumin decreased (&le;33%), hypoglycemia (&le;32%), hypokalemia (12% to 29%), hyperlipidemia (renal transplant: 21%), hyperkalemia (renal transplant: 18%), amenorrhea (&le;17%), hyponatremia (&le;16%), dyslipidemia (renal transplant: 15%), hypomagnesemia (renal transplant: 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Stomatitis (oncology uses: 44% to 86%; grade 3: 4% to 9%; grade 4: &lt;1%; renal transplant: 8%), diarrhea (14% to 50%; grade 3: &le;5%; grade 4: &lt;1%), constipation (10% to 38%), abdominal pain (3% to 36%), nausea (8% to 32%: grade 3: &le;2%; grade 4: &lt;1%), appetite decreased (6% to 30%), anorexia (1% to 30%), vomiting (15% to 29%; grade 3: &le;2%; grade 4: &lt;1%), weight loss (9% to 28%), taste alteration (1% to 22%), gastroenteritis (1% to 18%), xerostomia (8% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (5% to 22%), dysuria (renal transplant: 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (26% to 92%; grades 3/4: &le;15%; grade 4: &lt;1%), PTT increased (SEGA: 72%), leukopenia (oncology uses: 26% to 58%; renal transplant 3%), lymphocytopenia (20% to 54%; grades 3/4: &le;18%), thrombocytopenia (19% to 54%; grade 3: &le;3%; renal transplant &lt;10%), neutropenia (14% to 46%; grades 3/4: &le;9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: AST increased (23% to 89%; grade 3: &le;4%; grade 4: &lt;1%), alkaline phosphatase increased (32% to 74%), ALT increased (18% to 51%; grade 3: &le;4%; grade 4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (13% to 33%), arthralgia (&le;20%), back pain (11% to 15%), limb pain (8% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Otitis (6% to 36%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (11% to 50%), hematuria (renal transplant: 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory infection (11% to 82%), sinusitis (3% to 39%), cough (7% to 30%), dyspnea (20% to 24%; grade 3: 2% to 6%; grade 4: &le;1%), epistaxis (&le;22%), pneumonitis (includes alveolitis, interstitial lung disease, lung infiltrate, pulmonary alveolar hemorrhage, pulmonary toxicity; 1% to 19%; grade 3: 3% to 4%; grade 4: &lt;1%), nasal congestion (14%), rhinitis (14%), pharyngitis (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (13% to 62%; grade 3: 4% to 7%; grade 4: 1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Chest pain (5%), tachycardia (3%), heart failure (1%), angina, atrial fibrillation, chest discomfort, deep vein thrombosis, edema (generalized), hypotension, palpitation, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Depression (5%), migraine (5%), chills (4%), agitation, hallucination, hemiparesis, hypesthesia, malaise, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Eczema (10%), alopecia (&le;10%), palmar-plantar erythrodysesthesia syndrome ([hand-foot syndrome] 5%), papule (5%), erythema 4%, onychoclasis (4%), pityriasis rosea (4%), skin lesions (4%), hirsutism, incision complications, hyperhydrosis, hypertrichosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Menorrhagia (6% to 10%), menstrual irregularities (6% to 10%), diabetes mellitus (exacerbation: 2%; new-onset: &lt;10%), dysmenorrhea (6%), metrorrhagia (6%), cushingoid syndrome, dehydration, gout, hypercalcemia, hyperparathyroidism, hyperphosphatemia, hyperuricemia, iron deficiency, vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Gastritis (7%), hemorrhoids (5%), dyspepsia (4%), dysphagia (4%), ageusia (1%), abdominal distention, epigastric discomfort, flatulence, gastroesophageal reflux, gingival hypertrophy, hematemesis, ileus, peritonitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Vaginal hemorrhage (8%), bladder spasm, erectile dysfunction, ovarian cysts, pollakiuria, polyuria, pyuria, scrotal edema, urinary retention, urinary urgency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Hemorrhage (3%), leukocytosis, lymphadenopathy, thrombocythemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Bilirubin increased (3% to 10%; grades 3/4: &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Muscle spasm (&le;10%), tremor (8%), paresthesia (5%), jaw pain (3%), joint swelling, musculoskeletal pain, myalgia, osteonecrosis, osteopenia, osteoporosis, spondylitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Eyelid edema (4%), ocular hyperemia (4%), conjunctivitis (2%), blurred vision, cataract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Renal failure (3%), BUN increased, hydronephrosis, interstitial nephritis, proteinuria, renal artery thrombosis, renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pleural effusion (7%), nasopharyngitis (6%), pneumonia (6%), bronchitis (4%), pharyngolaryngeal pain (4%), rhinorrhea (3%), atelectasis, nasal congestion, pulmonary edema, sinus congestion, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Hypersensitivity (3%; includes anaphylaxis, dyspnea, flushing, chest pain, angioedema), BK virus infection, candidiasis, night sweats",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Aspergillosis, azoospermia, cardiac arrest, fluid accumulation, graft thrombosis, hepatic cholestasis, hepatitis B reactivation, lymphoma, oligospermia, pancreatitis, pancytopenia, polyoma virus infection (BK virus), progressive multiple leukoencephalopathy (PML), pulmonary embolism, respiratory distress, sepsis, skin cancer, synovitis (severe), testosterone levels decreased, thrombotic microangiopathy/thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TMA/TTP/HUS), wound healing impaired",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7674098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to everolimus, sirolimus, other rapamycin derivatives, or any component of the formulation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7674099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angioedema: Everolimus is associated with the development of angioedema; concomitant use with other agents known to cause angioedema (eg, ACE inhibitors) may increase the risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bone marrow suppression: Decreases in hemoglobin, neutrophils, platelets, and lymphocytes have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Edema: Generalized edema (including peripheral edema and lymphedema) and local fluid accumulation (eg, pericardial effusion, pleural effusion, ascites) may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fertility effects: Azoospermia and oligospermia have been observed in males.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Graft thrombosis:",
"     <b>",
"      [U.S. Boxed Warning]: An increased risk of renal arterial and venous thrombosis has been reported with use in renal transplantation, generally within the first 30 days after transplant; may result in graft loss.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic artery thrombosis: MTOR inhibitors are associated with an increase in hepatic artery thrombosis, most cases have been reported within 30 days after transplant and usually proceeded to graft loss or death. Do not use everolimus prior to 30 days post liver transplant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infections:",
"     <b>",
"      [U.S. Boxed Warning]: Everolimus has immunosuppressant properties which may result in infection;",
"     </b>",
"     the risk of developing bacterial (including mycobacterial), viral, fungal, and protozoal infections and for local, opportunistic (including polyomavirus infection), systemic infections, and/or sepsis is increased. Polyoma virus infection in transplant patients may be serious and/or fatal. Polyoma virus-associated nephropathy (due to BK virus), which may result in serious cases of deteriorating renal function and renal graft loss, has been observed with use in renal transplantation. JC virus-associated progressive multiple leukoencephalopathy (PML) may also be associated with everolimus use in transplantation. Reduced immunosuppression (taking into account the risks of rejection) should be considered with evidence of polyoma virus infection or PML. Reactivation of hepatitis B has been observed in patients receiving everolimus. Resolve pre-existing invasive fungal infections prior to treatment initiation. Transplant recipient patients should receive prophylactic therapy for",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP); and for cytomegalovirus (CMV). Monitor for signs and symptoms of infection during treatment. Discontinue if invasive systemic fungal infection is diagnosed (and manage with appropriate antifungal therapy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Immunosuppressant use may result in the development of malignancy, including lymphoma and skin cancer.",
"     </b>",
"     The risk is associated with treatment intensity and the duration of therapy. To minimize the risk for skin cancer, limit exposure to sunlight and ultraviolet light; wear protective clothing, and use effective sunscreen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Mucositis/stomatitis: Use is associated with mouth ulcers, mucositis, and stomatitis; manage with topical therapy; avoid the use of alcohol-, peroxide-, iodine-, or thyme-based mouthwashes. Due to the high potential for drug interactions, avoid the use of systemic antifungals unless fungal infection has been diagnosed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Nephrotoxicity: Elevations in serum creatinine (generally mild), renal failure, and proteinuria have been observed with everolimus use; monitor renal function (BUN, creatinine, and/or urinary protein). Risk of nephrotoxicity may be increased when administered with calcineurin inhibitors (eg, cyclosporine, tacrolimus); dosage adjustment of calcineurin inhibitor is necessary. Monitor for proteinuria; the risk of proteinuria is increased when everolimus is used in combination with cyclosporine, and with higher serum everolimus concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pneumonitis: Noninfectious pneumonitis (sometimes fatal) has been observed with mTOR inhibitors, including everolimus; symptoms include dyspnea, cough, hypoxia and/or pleural effusion; promptly evaluate worsening respiratory symptoms. May require treatment interruption followed by dose reduction (pneumonitis has developed even with reduced doses) and/or corticosteroid therapy; discontinue for grade 4 symptoms. Imaging may overestimate the incidence of clinical pneumonitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Wound healing complication: Everolimus use may delay wound healing and increase the occurrence of wound-related complications (eg, wound dehiscence, infection, incisional hernia, lymphocele, seroma); may require surgical intervention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes: Increases in serum glucose are common; may alter insulin and/or oral hypoglycemic therapy requirements in patients with diabetes. The risk for new-onset diabetes is increased with everolimus use after transplantation. Achieve optimal glucose levels prior to treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heart transplantation:",
"     <b>",
"      [U.S. Boxed Warning]: Increased mortality (usually associated with infections) within the first 3 months after transplant was noted in a study of patients with",
"      <i>",
"       de novo",
"      </i>",
"      heart transplant receiving immunosuppressive regimens containing everolimus (with or without induction therapy). Use in heart transplantation is not recommended.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Everolimus exposure is increased in patients with hepatic impairment. For patients with breast cancer, PNET, RCC, or renal angiomyolipoma with mild and moderate hepatic impairment, reduced doses are recommended; in patients with severe hepatic impairment, use is recommended (at reduced doses) if the potential benefit outweighs risks. For patients with SEGA, reduced doses may be needed (based on therapeutic drug monitoring) for mild and moderate hepatic impairment, and are recommended in severe hepatic impairment; monitor whole blood trough levels. Reduced doses are also recommended in transplant patients with hepatic impairment (Child-Pugh class A, B, or C); monitor whole blood trough levels closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hereditary galactose intolerance: Avoid use in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption; may result in diarrhea and malabsorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperlipidemia: Use with caution in patients with hyperlipidemia; may increase serum lipids (cholesterol and triglycerides). Higher serum concentrations are associated with an increased risk for hyperlipidemia. Use has not been studied in patients with baseline cholesterol &gt;350 mg/dL. Antihyperlipidemic therapy may not normalize levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: An increased incidence of rash, infection and dose interruptions have been reported in patients with renal insufficiency (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;60 mL/minute) who received mTOR inhibitors for the treatment of renal cell cancer (Gupta, 2011). Pharmacokinetic studies have not been conducted; dosage adjustments are not required based on renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Transplantation (solid organ): The safety and efficacy of everolimus in renal transplantation patients with high-immunologic risk  or in solid organ transplant other than renal or liver have not been established. In liver transplant, tacrolimus has minimal or no pharmacokinetic impact on everolimus concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Calcineurin inhibitor combination therapy:",
"     <b>",
"      [U.S. Boxed Warning]: Due to the increased risk for nephrotoxicity in renal transplantation, avoid standard doses of cyclosporine in combination with everolimus; reduced cyclosporine doses are recommended when everolimus is used in combination with cyclosporine.",
"     </b>",
"     Therapeutic monitoring of cyclosporine and everolimus concentrations is recommended. Everolimus and cyclosporine combination therapy may result in increased proteinuria and may increase the risk for thrombotic microangiopathy/thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TMA/TTP/HUS); monitor blood counts. In liver transplantation, the tacrolimus dose and target range should be reduced to minimize the risk of nephrotoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; HMG-CoA reductase inhibitors: In transplant patients, avoid the use of certain HMG-CoA reductase inhibitors (eg, simvastatin, lovastatin); may increase the risk for rhabdomyolysis due to the potential interaction with cyclosporine (which may be given in combination with everolimus for transplantation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Tablet formulations: Tablets (Afinitor&reg;, Zortress&reg;) and tablets for oral suspension (Afinitor&reg; Disperz) are not interchangeable; Afinitor&reg; Disperz is only indicated in conjunction with therapeutic monitoring for the treatment of SEGA. Do not combine formulations to achieve desired dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Continue treatment with everolimus for renal cell cancer as long as clinical benefit is demonstrated or until occurrence of unacceptable toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Assay method: For indications requiring whole blood trough concentrations to determine dosage adjustments, a consistent method should be used; concentration values from different assay methods may not be interchangeable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: In transplantation, everolimus should only be used by physicians experienced in immunosuppressive therapy and management of transplant patients. Adequate laboratory and supportive medical resources must be readily available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunizations: Patients should not be immunized with live viral vaccines during or shortly after treatment and should avoid close contact with recently vaccinated (live vaccine) individuals. In pediatric patients treated for SEGA, complete recommended series of live virus childhood vaccinations prior to treatment (if immediate everolimus treatment is not indicated); an accelerated vaccination schedule may be appropriate.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7710406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Everolimus may enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Everolimus. Management: When using everolimus for renal cell carcinoma, avoid concurrent cyclosporine.  When using everolimus as post-transplant immunosuppression, concurrent cyclosporine should be used at lower doses and with lower target serum cyclosporine concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Everolimus. Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Everolimus. Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Everolimus. Management: Closely monitor everolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of everolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Everolimus. Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Everolimus. Management: Concurrent use of Afinitor brand everolimus with St Johns wort (SJW) is not recommended. Zortress brand everolimus prescribing information cautions that SJW may decrease everolimus concentrations, though no specific dose adjustment is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7674191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may increase levels of everolimus. Absorption with food may be variable. Management: Avoid grapefruit juice. Take with or without food, but be consistent with regard to food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease the levels of everolimus. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7674093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (Afinitor&reg;) / C (Zortress&reg;) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7674094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxicity, fetotoxicity, malformations, and growth retardation were observed in animal reproduction studies with exposures lower than expected with human doses. Based on the mechanism of action, may cause fetal harm if administered during pregnancy. Women of childbearing potential should be advised to avoid pregnancy. Women of childbearing potential should use highly effective birth control during treatment, and continue for 8 weeks after everolimus discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7674096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7674097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if everolimus is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7674200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid grapefruit juice. May be taken with or without food, although should be administered consistently with regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Afinitor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (1): $313.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (1): $319.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (28): $9180.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $336.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zortress Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (60): $450.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (1): $15.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75 mg (1): $22.51",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7674218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (baseline and periodic), liver function; serum creatinine, urinary protein, and BUN (baseline and periodic); fasting serum glucose and lipid profile (baseline and periodic); monitor for signs and symptoms of infection, noninfectious pneumonitis, or malignancy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     For liver or renal transplantation, monitor everolimus whole blood trough concentrations (based on an LC/MS/MS assay method), especially in patients with hepatic impairment, with concomitant CYP3A4 inhibitors and inducers, and when cyclosporine formulations or doses are changed; dosage adjustments should be made on trough concentrations obtained 4-5 days after a previous dosage adjustment; monitor cyclosporine concentrations; monitor for proteinuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     For SEGA, monitor everolimus whole blood trough concentrations ~2 weeks after treatment initiation, 2 weeks after dose modifications and after initiation or dose modification of concomitant CYP3A4 and/or P-gp inducers or inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F10223954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommended range for everolimus whole blood trough concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liver and renal transplantation: 3-8 ng/mL (based on an LCMSMS assay method)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Subependymal giant cell astrocytoma (SEGA): 5-15 ng/mL (high concentrations may be associated with larger reductions in SEGA volumes, responses have been observed at concentrations as low as 5 ng/mL)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Afinitor (AU, CZ, EE, GB, HK, ID, IL, KP, MY, NZ, PH, SE, SG, TH, TW);",
"     </li>",
"     <li>",
"      Certican (AR, AT, AU, BE, BG, BR, CH, CN, CO, CZ, DE, DK, EC, EE, FI, FR, GR, HK, HN, ID, IL, IN, IT, KP, MY, NL, NO, NZ, PE, PH, PK, PL, PT, SE, SG, TH, TW, UY, VE);",
"     </li>",
"     <li>",
"      Votubia (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7674209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Everolimus is a macrolide immunosuppressant and an m-TOR inhibitor which has antiproliferative and antiangiogenic properties, and also reduces lipoma volume in patients with angiomyolipoma. Reduces protein synthesis and cell proliferation by binding to the FK binding protein-12 (FKBP-12), an intracellular protein, to form a complex that inhibits activation of mTOR (mammalian target of rapamycin) serine-threonine kinase activity. Also reduces angiogenesis by inhibiting vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF-1) expression. Angiomyolipomas may occur due to unregulated mTOR activity in TSC-associated renal angiomyolipoma (Budde, 2012); everolimus reduces lipoma volume (Bissler, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7674192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid, but moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~74%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensively metabolized in the liver via CYP3A4; forms 6 weak metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablets: ~30%; systemic exposure reduced by 22% with a high-fat meal and by 32% with a light-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablets for suspension: AUC equivalent to tablets although peak concentrations are 20% to 36% lower; steady state concentrations are similar",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (80%, based on solid organ transplant studies); Urine (~5%, based on solid organ transplant studies)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Amato RJ, Jac J, Geissinger S, et al, &ldquo;A Phase 2 Study With a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients With Metastatic Clear Cell Renal Cell Cancer,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2009, 115(11):2438-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/19306412/pubmed\" id=\"19306412\" target=\"_blank\">",
"        19306412",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Appleby L, Morrissey S, Bellmunt J, et al, &ldquo;Management of Treatment-Related Toxicity With Targeted Therapies for Renal Cell Carcinoma: Evidence-Based Practice and Best Practices,&rdquo;",
"      <i>",
"       Hematol Oncol Clin North Am",
"      </i>",
"      , 2011, 25(4):893-915.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/21763973/pubmed\" id=\"21763973\" target=\"_blank\">",
"        21763973",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bachelot T, Bourgier C, Cropet C, et al, &ldquo;Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor&ndash;Positive, Human Epidermal Growth Factor Receptor 2&ndash;Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(22):2718-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/22565002/pubmed\" id=\"22565002\" target=\"_blank\">",
"        22565002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baselga J, Campone M, Piccart M, et al, &ldquo;Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(6):520-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/22149876/pubmed\" id=\"22149876\" target=\"_blank\">",
"        22149876",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bissler JJ, Kingswood JC, Zonnenberg BA, et al, &ldquo;Everolimus Therapy for Angiomyolipoma in Patients With Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis: Results From EXIST-2,&rdquo;",
"      <i>",
"       J Clin Oncology",
"      </i>",
"      , 2012, 30(supp 5):356  [abstract 356 from 2012 ASCO Genitourinary Cancers Symposium].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bracarda S, Hutson TE, Porta C, et al, &ldquo;Everolimus in Metastatic Renal Cell Carcinoma Patients Intolerant to Previous VEGFr-TKI Therapy: A RECORD-1 Subgroup Analysis,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2012, 106(9):1475-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/22441644/pubmed\" id=\"22441644\" target=\"_blank\">",
"        22441644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Budde K and Gaedeke J, &ldquo;Tuberous Sclerosis Complex-Associated Angiomyolipomas: Focus on mTOR Inhibition,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2012, 59(2):276-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/22130643/pubmed\" id=\"22130643\" target=\"_blank\">",
"        22130643",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Simone P, Nevens F, De Carlis L, et al, &ldquo;Everolimus With Reduced Tacrolimus Improves Renal Function in",
"      <i>",
"       de novo",
"      </i>",
"      Liver Transplant Recipients: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Am J Transplant",
"      </i>",
"      , 2012, 12(11):3008-20. PMID: 22882750",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/22882750/pubmed\" id=\"22882750\" target=\"_blank\">",
"        22882750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eisen HJ, Tuzcu EM, Dorent R, et al, &ldquo;Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(9):847-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/12944570/pubmed\" id=\"12944570\" target=\"_blank\">",
"        12944570",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Franz DN, Krueger DA, Care MM, et al, &ldquo;Everolimus for Subependymal Giant-Cell Astrocytomas (SEGAs) in Tuberous Sclerosis (TS),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(15s):2004 [abstract 2004 from 2010 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghobrial IM, Gertz M, Laplant B, et al, &ldquo;Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(8):1408-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/20142598/pubmed\" id=\"20142598\" target=\"_blank\">",
"        20142598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta S, Parsa VB, Heilbrun LK, et al, &ldquo;Safety and Efficacy of Molecularly Targeted Agents in Patients With Metastatic Kidney Cancer With Renal Dysfunction,&rdquo;",
"      <i>",
"       Anticancer Drugs",
"      </i>",
"      , 2011, 22(8):794-800.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/21799472/pubmed\" id=\"21799472\" target=\"_blank\">",
"        21799472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hainsworth JD, Spigel DR, Burris HA 3rd, et al, &ldquo;Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(13):2131-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/20368560/pubmed\" id=\"20368560\" target=\"_blank\">",
"        20368560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hill JA, Hummel M, Starling RC, et al, &ldquo;A Lower Incidence of Cytomegalovirus Infection in",
"      <i>",
"       de novo",
"      </i>",
"      Heart Transplant Recipients Randomized to Everolimus,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2007, 84(11):1436-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/18091519/pubmed\" id=\"18091519\" target=\"_blank\">",
"        18091519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kato TS, Sasaoka T, Wada K, et al, &ldquo;Reversible Severe Synovitis Associated With Everolimus,&rdquo;",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2010, 29(6):710-1.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirchner GI, Meier-Wiedenbach I, and Manns MP, &ldquo;Clinical Pharmacokinetics of Everolimus,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2004, 43(2):83-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/14748618/pubmed\" id=\"14748618\" target=\"_blank\">",
"        14748618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kovarik JM, Sabia HD, Figuerierdo J, et al, &ldquo;Influence of Hepatic Impairment on Everolimus Pharmacokinetics: Implications for Dose Adjustment,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2001, 70(5):425-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/11719728/pubmed\" id=\"11719728\" target=\"_blank\">",
"        11719728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krueger DA, Care MM, Holland K, et al, &ldquo;Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(19):1801-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/21047224/pubmed\" id=\"21047224\" target=\"_blank\">",
"        21047224",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lorber MI, Mulgaonkar S, Butt KM, et al, &ldquo;Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in",
"      <i>",
"       de novo",
"      </i>",
"      Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2005, 80(2):244-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/16041270/pubmed\" id=\"16041270\" target=\"_blank\">",
"        16041270",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lorber MI, Ponticelli C, Whelchel J, et al, &ldquo;Therapeutic Drug Monitoring for Everolimus in Kidney Transplantation Using 12-Month Exposure, Efficacy, and Safety Data,&rdquo;",
"      <i>",
"       Clin Transplant",
"      </i>",
"      , 2005, 19(2):145-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/15740547/pubmed\" id=\"15740547\" target=\"_blank\">",
"        15740547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Motzer RJ, Escudier B, Oudard S, et al, &ldquo;Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomised, Placebo-Controlled Phase III Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 372(9637):449-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/18653228/pubmed\" id=\"18653228\" target=\"_blank\">",
"        18653228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Motzer RJ, Escudier B, Oudard S, et al, &ldquo;Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma: Final Results and Analysis of Prognostic Factors,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2010, 116(18):4256-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/20549832/pubmed\" id=\"20549832\" target=\"_blank\">",
"        20549832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Donnell A, Faivre S, Burris HA 3rd, et al, &ldquo;Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(10):1588-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/18332470/pubmed\" id=\"18332470\" target=\"_blank\">",
"        18332470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pascual J, del Castillo D, Cabello M, et al, &ldquo;Interaction Between Everolimus and Tacrolimus in Renal Transplant Recipients: A Pharmacokinetic Controlled Trial,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2010, 89(8):994-1000.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/20335831/pubmed\" id=\"20335831\" target=\"_blank\">",
"        20335831",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pavel ME, Hainsworth JD, Baudin E, et al, &ldquo;Everolimus Plus Octreotide Long-Acting Repeatable for the Treatment of Advanced Neuroendocrine Tumours Associated With Carcinoid Syndrome (RADIANT-2): A Randomised, Placebo-Controlled, Phase 3 Study,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2011, 378(9808):2005-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/22119496/pubmed\" id=\"22119496\" target=\"_blank\">",
"        22119496",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Porta C, Calvo E, Climent MA, et al, &ldquo;Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial,&rdquo;",
"      <i>",
"       Eur Urol",
"      </i>",
"      , 2012, 61(4):826-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/22297244/pubmed\" id=\"22297244\" target=\"_blank\">",
"        22297244",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tabernero J, Rojo F, Calvo E, et al, &ldquo;Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(10):1603-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/18332469/pubmed\" id=\"18332469\" target=\"_blank\">",
"        18332469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tillema JM, Leach JL, Krueger DA, et al, &ldquo;Everolimus Alters White Matter Diffusion in Tuberous Sclerosis Complex,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(8):526-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/22262746/pubmed\" id=\"22262746\" target=\"_blank\">",
"        22262746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vandewiele B, Vandecasteele SJ, Vanwalleghem L, et al, &ldquo;Diffuse Alveolar Hemorrhage Induced by Everolimus,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2010, 137(2):456-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/20133293/pubmed\" id=\"20133293\" target=\"_blank\">",
"        20133293",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vigan&ograve; M, Tuzcu M, Benza R, et al, &ldquo;Prevention of Acute Rejection and Allograft Vasculopathy by Everolimus in Cardiac Transplants Recipients: A 24-Month Analysis,&rdquo;",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2007, 26(6):584-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/17543781/pubmed\" id=\"17543781\" target=\"_blank\">",
"        17543781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Villarrheal-Garza C, Cortes J, Andre F, et al, &ldquo;mTOR Inhibitors in the Management of Hormone Receptor-Positive Breast Cancer: The Latest Evidence and Future Directions,&rdquo;",
"      <i>",
"       Ann Oncology",
"      </i>",
"      , 2012, 23(10):2526-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/22553196/pubmed\" id=\"22553196\" target=\"_blank\">",
"        22553196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yao JC, Lombard-Bohas C, Baudin E, et al, &ldquo;Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(1):69-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/19933912/pubmed\" id=\"19933912\" target=\"_blank\">",
"        19933912",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yao JC, Phan AT, Chang DZ, et al, &ldquo;Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(26):4311-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/18779618/pubmed\" id=\"18779618\" target=\"_blank\">",
"        18779618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yao JC, Shah MH, Ito T, et al, &ldquo;Everolimus for Advanced Pancreatic Neuroendocrine Tumors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(6):514-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/21306238/pubmed\" id=\"21306238\" target=\"_blank\">",
"        21306238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zuckermann A, Manito N, Epailly E, et al,  &ldquo;Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation,&rdquo;",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2008, 27(2):141-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/4/6218/abstract-text/18267219/pubmed\" id=\"18267219\" target=\"_blank\">",
"        18267219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9078 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6218=[""].join("\n");
var outline_f6_4_6218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10223925\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7418605\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13209898\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674090\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674213\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10953367\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674214\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674215\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674216\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674217\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674251\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674088\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14949342\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10223926\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674201\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674091\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674092\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674085\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674166\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674098\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674099\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837969\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7710406\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674191\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674093\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674094\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674096\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674097\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674200\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321944\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674218\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10223954\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961948\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674209\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674192\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9078\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9078|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/11/38070?source=related_link\">",
"      Everolimus: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/41/20121?source=related_link\">",
"      Everolimus: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_4_6219="Clin syndrome Lyme";
var content_f6_4_6219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathophysiology of clinical syndromes with neurobehavioral involvement",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Manifestation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antimicrobial response",
"       </td>",
"       <td class=\"subtitle1\">",
"        Organisms demonstrable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Multifocal inflammatory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningitis",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Minority",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuropathy",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalomyelitis",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalopathy",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6219=[""].join("\n");
var outline_f6_4_6219=null;
var title_f6_4_6220="Source control in sepsis";
var content_f6_4_6220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Source control methods for common ICU infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sinusitis",
"       </td>",
"       <td>",
"        Surgical decompression of the sinuses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia",
"       </td>",
"       <td>",
"        Chest physiotherapy, suctioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Empyema thoracis",
"       </td>",
"       <td>",
"        Drainage, decortication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mediastinitis",
"       </td>",
"       <td>",
"        Drainage, debridement, diversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peritonitis",
"       </td>",
"       <td>",
"        Resection, repair, or diversion of ongoing sources of",
"contamination, drainage of abscesses, debridement of necrotic tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholangitis",
"       </td>",
"       <td>",
"        Bile duct decompression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic infection",
"       </td>",
"       <td>",
"        Drainage or debridement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract",
"       </td>",
"       <td>",
"        Drainage of abscesses, relief of obstruction, removal",
"or changing of infected catheters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Catheter-related bacteremia",
"       </td>",
"       <td>",
"        Removal of catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endocarditis",
"       </td>",
"       <td>",
"        Valve replacement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septic arthritis",
"       </td>",
"       <td>",
"        Joint drainage and debridement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft tissue infection",
"       </td>",
"       <td>",
"        Debridement of necrotic tissue and drainage of discrete",
"abscesses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prosthetic device infection",
"       </td>",
"       <td>",
"        Device removal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Marshall, JC, Lowry, SF. Evaluation of the adequacy of source control. In: Sibbald, WJ, Vincent, JL, Clinical Trials for the Treatment of Sepsis. Springer-Verlag, Berlin, 1995 p 329.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6220=[""].join("\n");
var outline_f6_4_6220=null;
var title_f6_4_6221="GBS antigens for vaccine use";
var content_f6_4_6221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential antigens of group B streptococcus for use as vaccines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Antigen",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Virulence factor",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Studies performed with prototype vaccines:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Preclinical",
"       </td>",
"       <td class=\"subtitle2\">",
"        Clinical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Carbohydrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        group B antigen",
"       </td>",
"       <td>",
"        no",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ia CPS",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        Phases 1 and 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ib CPS",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        Phases 1 and 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        II CPS",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        Phases 1 and 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        III CPS",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        Phases 1 and 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        V CPS",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        Phase 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        VI CPS",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        VIII CPS",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Proteins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\" rowspan=\"1\">",
"        C proteins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        alpha",
"       </td>",
"       <td class=\"sublist_other\">",
"        yes",
"       </td>",
"       <td class=\"sublist_other\">",
"        yes",
"       </td>",
"       <td class=\"sublist_other\">",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"1\">",
"        beta",
"       </td>",
"       <td class=\"sublist_other\">",
"        ?",
"       </td>",
"       <td class=\"sublist_other\">",
"        yes",
"       </td>",
"       <td class=\"sublist_other\">",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        epsilon",
"       </td>",
"       <td class=\"sublist_other\">",
"        ?",
"       </td>",
"       <td class=\"sublist_other\">",
"        no",
"       </td>",
"       <td class=\"sublist_other\">",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rib",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        R-proteins",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        no",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type V/VIII alpha-like proteins",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C5a peptidase",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        no",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sip",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        yes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CPS: capsular polysaccharide.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6221=[""].join("\n");
var outline_f6_4_6221=null;
var title_f6_4_6222="Mean weight change orlistat";
var content_f6_4_6222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Orlistat promotes weight loss and limits weight regain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 334px; background-image: url(data:image/gif;base64,R0lGODlhngFOAeYAAP///4CAgAAAAMDAwEBAQODg4BAQEPDw8KCgoNDQ0CAgIPDz+YCZzP8AADAwMAAzmWBgYP/AwP/w8P9AQJCQkEBms6Cz2f+AgLCwsBBAn/8QEP+goFBQUP9QUMDN5v8wMP/Q0ODm83CNxlBzuf9gYP/g4NDZ7HBwcCBNpmCAv/9wcP+wsDBZrP8gIP+QkLDA35Cm0z8mcp8jSW8cVu9zek8jaYBJfKCjye/j6S8pfN82Q6BzmVBiqX9pnJ8TOR8shVBTmQ8vj+9TWb+Mpl9Qj58yWa8PL38ZTO/Dyd8mMu8DCT9Wop+TuXA8du9jac+pvO9DSdDJ3N92g8+ZrN/G069gf385bM8JHIApXM9pfICJvM9ZbAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACeAU4BAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocyA5DgAADCCpcqGiAgIcCMDCcSLFAQgoCCFDcOBGBAAiDEBwcGaAAx5P4DigwYFKQSJIKEqKcKS/BygSKCMikyZPdAAMfDybS2bOougAQHw7dabSpPKJOo8KDKrXqOqpWs5rDqrVrOK5ew3IDK7bsNbJm00pDq7ZtM7Zu/+NWSqARwAECLVXBlcv3UQKMAwZgEMAU1d6+iHMmfZg31eHEkAshgCBgZGHDlyNrRnQgs17Pm0MPCkCgNAGcqx6LTuwxKehRqlf3RYraVWzZchMIOADrNm63CQw4MF3b8evfiB26ZuUbuXNPzZ+XxcDhBPVW0aV71Z2xgIDimLVvDqAAg0bCzI+LVxvAwQCd39Ovj+x9pQEF2NXPN4tAgQAH4IW3H2IHIAQAAhTkNyBiCBjAm0MBmpLdgk6RNgh6qelHoVYNJuRRYwJu6NYBQD1UV4YiylUABAScwJt8KbZVQEm9aRhjVLrZGMqEN850gAMIBfbiZz2mpRxEOnLCY/+RHM1IEoinLMkkRwkkUECEmCRwEJaCSDklQz9mNNiQmgymgH8SIeLllwp5xMF5STLiwHe6ObCUIhcwsACbPJH23gEYbqIUAIMeSBJ5r00Qgwd80tRge5SRmcmghb40Ukx4zsBAozTN+dAJngB1AKAG3JlIBD6MwKmPIqXZCWUHfWRqIlegsCpKBVAQgKucHMDBQxxISsheEzyw560VlSgrjIm4sCiyFAVgAAIDUMYlbMeBoCm0E5l3YZyaHCaDqtwuVIABI1VGo3GMbGFruQoduRy7i7hgLLwEdRbYvgMIS8phIPgQAr7IPaZBCQT/9lgHPRybsGiPOcvowxDrp+3/phQHBAEF/pai2rgZB/Qruig2ksW7If9TwGQlM7LBvSnnQ5cgd0EpoYYlPBvzPX8RJlig9DbSBMY710PAYgLY7LGNO5BbND2TqWsgs4w8gfLT83QWS2wlwIy1PHfNS+QjRVDx9TwYKUAc1YyQcMHZ8mDUcYiNbDAB3PGcqzTdjJRwhMN4H4U00HwzssTEgauDgGmMXyuKbyIQnbhXvlnAw+Ts0MU4BI6D4psJP2C+jrwP4Tc2JA8gIXo63gJw7mDgXtJcBUOsjg55vAHqUOyWNCeCDbaf45DaQOV4+iMW1CBB8OZIK4ACCMzY8iOgr8C8VNE9QMP14QwQ/aF7YzsJ/xM6cA+On4vxLnvsDSxvfjdX6rvv3OJPMoH173+TK7UJfpJrABxTU+x6sL38wQ8op0naJ472EDsdIjsVAJ4BuUEBdMHpExgYlX8ykx0PBAFwE7yGn/BCuE74xySWOgimKMECC4RQGw7hgAIcUKpMHCkAg8AIqAwFE97BgAgv1AZlHoIATcivJSdY1gN5Z4IgICyI2LAI/S7xKwUchIPqQ8EUoGiNATiAAuHDxGJwaAgepcAKXKwGd57nIrZF4gU5AEEaqzEApJTwZpZYgPbmKI0DIIADQHFAGHekPgDcIAl8jMbwAjDF+lmiBRFI5DMKcAL/AKmRniskAFRAAklGo/+Cd1waJkCABRB68hgFYOB/BpnJTADBhadURgzBaBtNGtJpsTzGqLZmSxx4LZf4WBMPYAnMYNoSABbAZTGNdkw94mCZxBgAB3jlxkqM4AbQHIZyFHACVrZSExYAQjaHkStPEaCIx7uEM8cZjFz5B0npvMQOpMDOXyjHAJxLAOfiaYkVtKCevpAmOmvZiRbIEaDuWNMgbFBAhN7CjumrpiVGIAOH4mJxNCwNDTv3zU0kD38WtQUF6gIob0LnmIPQoxNC+lAD4GR3Ep2oDNzH0lmcCyIOimklkreBmtZCnwTYp04poUch+HQrKCVEBYxA06O+oj//4WhHOcGAGfTUqa//GB4BDJDT6W3CAznoAFZf0R6ahfJfSSXEA5TQ1LGmggIKMAmEhrpTHVzVraq4aQMVBIoNiBWvqwBqG+laCQm0j00SiIBiDwqCCdw1Eiq4mzYS0C+CgoIBUHhskSLQgM424AOJbcDb7NeAbISJiHz9RAWq8NcpcfZuHWiACzj7tgh0YAITcIEgShDZDlivBCSYAAnkOIEGrEC47nPBBHz7DIxAoD0K9CpVtXBY1zbgbhcQLW0BcAG3FXcDEtCABro7gRJo4AMXEC8AiksCFTRArO5VQWxBuoyRmjWtj1CoIV5QgQ5o9kacbUF6G1CC7UrABR34gGhd0ICrloDB3m1A/wSKKwgFA+C8ADBsa5NhEQzEJDDxke4m9OjXL3FWA8uN5HY/oAEXMPgC2Y2kILLrNhiXgMLrLe11BbHjZUBUbJ6grNL0awgURKG6m+2xILbbAEi69wIg+GwE/BrlD6wgAiporIQZLNb5Zle3y6jjodYVZKCQsYz4JUQKYOBf60p2yaIFwAY6W9y3rUDBcb5zZz9w4wZo4LrLk0BsNaACe3jqzIUgciFgkIISA5YZ0koiGVOIKFGYAAWGbeujgXFD3RikMi451ApDYaw2b3oYR/wxqNE8CguEwNGYS2wEXHCB2R40GWIGnycsUq2P2EzRh8j002RN68hO4M/XFS55W//QZGVvIAKa7oWqH5JmQSAF0cOqtiFMnbAHGxvZuK2xYp+ICBDM+gK33fMEVHABxfKC1/yqrIg7oSdYl0sCdmuA28bNCcVeILJ4Xu4FyG0L+cmbn50YgQWEzS0QkOC84EVFYjcwcFzoldqEvQQMVMVtTj24BYQmODkwUhoIsCTjlghBBuS8YTatILbMPQoBAgCqECO8Eyx4AcOnBAIVaKAFLoh289xjgCRqexHANoQIRACAjscI3yweLjzoUoA5OQCTCzz6IC7N8h6tgATX/S88OoP1rJsiAybYuXQUy/YVwFgFLRCwyN0Rv3iXvRNJN8Samy52tUwcxuTFLW6R7dn/Dwget4CXMT3QB+TCgeIFLOh6WgpMa9zSeQKAny3bIzD3f3jPSSMxKd61nlJjqV0q/o4ss1HstmcL/STSswsjUY4JV/M9Kpw8drPZ7W6tOOS+tNeEvXtCgg/MtvNaUSVEpHpSVZweJRL4AGjdcoI5mQbbjr/ssYLbk+iT4PVhif0r8m4IhQsi+qNFCQha0Mm4fF7X8/7ExgcBAg3QlyL1L7RcGA/P+HtC5YSwAgfDERGgAX1nFnXHL3enJKRHCDlHCCrwARsxZwfYFga3gJtAfkrHdITwAe23EBugAbeGGBd3Vo5UClxHCOFVgfzwcCOIGEjBAaEXfJiAdoVQgC/4/w/Fl4N94RG8lAp7VwgXMH0AIWhEqBnnQi1CQoOXAHmH0AEttw/RNwHgJxek04BLlAp6ZEoSAHT+UAIeKBugdxCix4CqYHuGEGU8WA/194Ffo4GREIJV+A71B2aigQAnoDlr43+hoCeIwH34EIIsOBvw0XhRgoWFMAIcaAjodw8heH9nA4eHEAIPMDCHUH+KJw/ptYZYI4mHIALKRAghiHzr4IKi44mGsAAZgDiGEIHxAIZHODmoaAgMUAGK8AH61w4CmIuniIiHgALEZAjmBYnn4HPEiBypZIh41AoWcDWGIICcGA6wSIq/gRTDURrMN3qvUAGSYwhDOIfcsIsL4v+DpOBHQpGFruABGWBKhCBcxWh/GxJUM1hmGWE6rPYKfpgIK0gO07ghg6GMmOAf1zKLlYCD4iCOIoIUGDA/QfY8/sEBodZDvuACLQCO0iABxhgjetMJN+QQ7jEnRURpo4aP7EgIUOgNEdAC5XUjV5gJR6QbGnFt6AgLI5ACi9CFdogNEvBwOZkieoiNn4Amc4JFsqCKrHiJDRCNzyCAHWCRRZMAczItAjQLMOCMhzCK1nBjLXCMPskig8WHqcCNjOBzmQgNLkBoTtkPC+AB+agLF+dAYIkKJlCJLjNe0QAC0leWBLGWDDACKPAAFSAClqgL5CFXJvg4vtgItdgIeNn/lM1QAtmVfgrRl38ZmBZgAsBQVnZxmIRUCwsAjI0gaAalDC/3XkqZDyaQjxZwmcWgG8RTQ3GZCupYkoZwloOoC5AZd0E3ECYgAiiQASkwmMgAVQCSWrTQloxQgG74C6VJAnrZD735mynwAs1AdjWSDNEXi7h5AbqZlu6Qmsfim8BJnc8AU+OXmKJQfN6pCs35nPfwAimAAigQnIJgAeQpDQ5ATbG5CsjZCAmGCwfWnfwQAsn0ACzAAJiZDS25n6pQk5HgfbUQAWAXc/XAl8fCACzwAAonnNnwk6fBhKZglA8ahrCAb3FXcfRgAhaQAhnKAoJZn/fJDXioNdeZC1Up/wnhJZmq4HAodpvoIAIVkAEZMAIMcJTi0B6/V6O5IJaRUH8+2gkbwGIqQI3swKJomA6tEVEMugpzyaGMaYCnwFsQlw/9mQ7Q1TggigqLKQkrkJSkYDcaIHX2EAIwQJvpIH6WpQufGYyPEIKnOQklsAJw1wIRZw8mkAIPQJ9tQZCUMJuT4KeZMGuR5Wfr5p7wwF8Z8KJxwaiUUKaOUHzP9qARgG7M9gEd0G5U6g4L0IwoUKd9wamqIF8KppIXEKqFkFikel0qYKv8wAAZUAF8Wg/7MwD9s6XIAAJul2DNlqvrtgF/ag8WYKTCikC6UYYZiJ6W4KmWgKy1+qwVqq33UP9BFsKZU8ULLGqnVvECKFAB6Lp4OkFC2AoAsFoJ8dmuTRECFYACMdoPMTRDsHlzuTACoYgSa+kBMMAAlmgBDLCwIvAA4KoPQyQAAwWwuKCK+8oQFgCkQfoAgFkBKYCw9bmwDCACCUoQUpSnwPAC67iXbAmyyFSkHuCluHIoCICBmTCvlyCwAKGiLGqgkSOznNCy0goAgQkAQGoOpJMRxlqUGXCx9lCLQkqkQ/sJiMoCf2mThgCYL4sIWosIFfAAiuQe3oMuNneIxaCy9uoOqwm0omABGioII/AALsQAl7kpWquwgvACI+CxHuC2KICwHrC3FQADAOABf1mkz6CZhGL/ntnnCw/bDuDpCnFLni/wtg+QARwLAFr7tcikoX05spdbAan5sV+7mpgLrM/gJqTxHeSqjeIBn/KpqKzwtRPjAVproIOwuWALAwZKt4LQtQuwcRm6KZwbDarEOQRgs+uDDCKQtuBAoHF7oCXrCg1LuADAu0zXtZpri8VbixybvbYIACyQATDAu8QLttIgZChLDCkQvuqAoRp6pbGgchlguhkwMNqru9crAn1ruSgQsw/wvw17vi8wvcyQa2QWNMWwAAdqDnR6LPaZCyYQtxqaoPnLvWCrrhw7AnvCAByrohz7tZuisg9gvc2woBTrCyawiuKwqkEqu6uBFBTAkEt7/wsWsLLe4AEp8KsW4Lx8MRjlKBIBNJPI0L7d4Jt/y7aicS7PRYaeECZH01WJFq+fwMDdaA0sOrW4gcKb4JHyekc46wkrrMXQ8LiyYXAHtwlh4gAKABI8dClUDAo37MPZhMDWegg3dAAmZ0m8IZJxrH3XYMa4sUYYhwlHhBE49CvYJ69/fA9zvCDSAgEQ0CDKqwge8ZESS8TNIMjFMMYUQhoUABKtGwknABRWNJXQoIjRYMUbAld1Msqu+wyUqMTGYMQbMiMrokQpbAyg+AyPnD9hPAoiygyenCKksYe7bAxrqgysnCJZWsjJbAygqQy2bMxlm6a/0IzL0Lw3ohuVfP+t1cCkALU4W3WNH1rDweCoxcDJ0jFtsGyG1cDOtvDLQRTMqeCyv1DMPQIBECkIHODG6EwMItC0v9DMPeIdxYoRd3yzjawKKruIu1DNPcK4jKvA1xACLMACtAwL9DzRqwYASBGv9swKA+20sqDPTOIfz0UZ/2rR2fDQt2DQUxIcOKWfZusNGM0CdEwKEv0l5khLxnnEOz0K3CxJIz0L+Hxqk3DUsrDDBnzPQ309TC0LbhusptDRiTTVsqCOEG0KKG3UDX0LJsACHHwKMu1JWj0LC5CvUS0JPY3WYb2kV/wJWA3X66DOofDVp5TWtaCpoHDWscTX2PDWgR3XvFDUnYD/2MUk2LZA2Eqdbe8A2I89CIxtC3pdCfLMRZU9zziscSjQ1hO02Y3tvpWgjk+92IbtC5L9CCpn1ag9D5fdCAzc1dkk2jbc2YRQsAebsCK7tw5l27fghxlbARvbsR/L2wy70dwzALVhjjWLytAKs8o9R1qitIJgff8B3ZM9DgxUF4MBkb9i08C93afgEHUhkzIpkk08Zuzd3u793vAd3/I93/Rd3/Z93/id3/q93/zd3/e90LwAUTJh3tYGauktautt322c3wuO3w1+3w9e3xGu4Aku4RU+3xOO4Reu4Qy+4fKd4R/u4R+e2psAby9C4ACgQwCQRMUK2UsdO9kR4+Ay/yEy/uI2fuOSUOM5zjvjbQk94x4HUB8DcEKanF8wfuSUEB00juQ7juORoONNHuVOvhbLAVXQo92QAOVPzuRbXglabuRTDuZh7ghKzuMkTgtfLuZS3uVrzuZtTuYzzuVuPudq/ubkkOZwnuRyXud0zud5bueNgOeBHudefuazED2UgOiToOiSwOiR4OiPAOmQIOmOQOmMYOmLgOmZvtCabsl33OmeTt6iPuqkXuqiriVT4wj/Y9OL8D8Tywid0Riurgio/upLiMcH4Sq17gi3vuq8Lm+zfggGVxvBngjFDgC3fgjwFhiCsOuKUOy+/uy6MlDHbgj/UxzVTgixPgjRPv8I6vsNHnEmH93qXDUnO+QIwSEc1s0I0vTRHmEABNDPiJAU594amSEvZETvl45x56Lu554I9g4A6W59eJwUdfHu8W7JAgDv8h7wiKBqgqDviDDwStvv5p4IFK8RGT/xXIUmLrHwCY/HiiwIFi8A507Ti5wNR7OQ674ILA4AovIISFFzAuAIEEFG9dFIRcQdJF8imWERB2LdO18oiKBXCfHyMW/sPg/SJk8oNW8IHhkYOJHzrf48ZGL0xh4YSWQ6Q//0hzDzTr/iApAgSW8IYK8UZ+/1hRDe9eE6Vq8INy8ISL8b1/0QKY8NCO9SZI4eR2MjNP0rr64IMpni/wEULV7/9M/TJaVxVn9kALzS9jmx+AnR91/8GqaBHn+fyVAP8hBgEhhBQ2OfCJ9v+IpP+YvgHxML+YeQ+UVE+aZvCKwv8EAB+GoSEWE/+qH/8Kvm+ugRaeN+FhCB7Oqu+YzA+zZSdSuhy4sw+EgBARgAFGEU3inOEq9vCNUnlYMg/aJP/Xzf/aBRQcmYEMgPFABNCPq0unbS/M8fXWb/EeufK9x/HOG+9rZf9GxM/pWf/8p+/7ICCAUOCgYCEACIiYgIAgYEAgIAAYYYhQWKipMBiI8DAJ0JAhiamKWmp6ipqqusqQkDsACFAKGRrByiAA4CCa0AuAMHCgKerKQAFAKbnagH/48InJDSxaeQiM4C0KmP0sS4GLq8qNzTwMLEqdbJy+im65/E5JDUpsPaANj3pubDA9/hvfYRO+dvYL9ToxgRQKYMHr1MDX/l2pVgUrdNvjJq3MgR1TAKyRS0YsQBgwCRviBQssRqgEoIngqcrGTgwClBAggECFDg1YBdFGxiCsCB6EkAOHXyROUT6AGSJlGeaiog6MtKAi4NLfpooUwFNIWW+hqWalBUk6Qm3am11FVLUI+eepuVbltFBTBg2AWOrIGaplwa8hRXZAFYL+92XMy4MaYEuwRwCMjqRCEHlFkdwCXAAThW3WwhGKYgM6YBoakxK4VhWM5eqLs9NLXacshn06eYbYbk2VRrSByEjj6JW9Hw0opWmzpQ6DOA2NNO7e782TbmZpx7T+8dmLfz48UBhEZkPfMxx+jTq1/Pvr379/Djy59Pv779+/jz69/Pv7///wAGKOCABBZo4IEIJqjgggw26OCDEEYo4YQUVmjhhRhmqOGGHHbo4YcghijiiCSWaOKJKKao4oostujiizDGKOOMNNZo44045qjjjjz26OOPQAYp5JBEFmnkkUgmqeSSTDbp5JNQRinllFRWaeWVWGap5YmBAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean body weight change during two-years treatment with orlistat or placebo in patients with type 2 diabetes. The patients initially received a reduced energy diet and at, one year, a weight maintenance diet. Orlistat therapy was associated with more weight loss and less weight regain. Although not shown, the orlistat group was randomly assigned to continued orlistat or placebo during the weight maintenance phase. Continued orlistat therapy was associated with less weight regain than in the two placebo groups (35 versus 51 and 63 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281:235.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6222=[""].join("\n");
var outline_f6_4_6222=null;
var title_f6_4_6223="Claw limb RSD";
var content_f6_4_6223=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F50460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F50460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Claw limb in complex regional pain syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A delay in the comprehensive treatment of complex regional pain syndrome (also termed reflex dystrophy) may result in progression to a useless claw-like limb. In this case, the patient ultimately recovered full use of the extremity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     By permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_4_6223=[""].join("\n");
var outline_f6_4_6223=null;
